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Abstract 
 
Extracellular signal-regulated protein kinase 5 (ERK5) is a member of the mitogen 
activated protein (MAP) kinase family which is specifically activated by 
mitogen/extracellular signal regulated kinase kinase-5 (MEK5).  Over recent years, 
abnormal MEK5/ERK5 signalling has been shown to be important in prostate 
carcinogenesis with increased levels of ERK5 immunoreactivity being associated with   
Gleason sum score (p<0.0001), bone metastases (p=0.0044) and locally advanced disease 
at diagnosis (p=0.0023).  In addition PC3 cells over-expressing ERK5 displayed enhanced 
proliferation, migration and invasion.  Taken together, these data suggest MEK5/ERK5 
pathway to be biological important in prostate cancer and a potential target in invasive 
prostate cancer. 
Using siRNA to target ERK5 expression, I found that reduced ERK5 expression 
significantly inhibited cellular proliferation, motility and invasion in prostate cancer PC3 
cells when compared to the controls, (p<0.005).  Our group has previously reported 
upregulated ERK5 expression in primary human prostate cancer specimens.  In this study, 
I was able to validate these results and demonstrate moderate-strong levels of cytoplasmic 
staining in 63% cases of PIN/PIA.  High levels of cytoplasmic (55%) and nucleur (73%) 
immunoreactivity was also shown in a range of metastatic prostate tumours (n=11).   
A number of similarities and interactions between ERK5 and ERK1/2 have recently been 
identified and there is suggestion that ERK5 may in fact regulate some of the cellular 
functions originally attributed to ERK1/2.  Potential ‘cross-talk’ between ERK5 and 
ERK1/2 signalling was investigated using siRNA for each individual isoform of ERK1/2.  
ERK1 knockdown resulted in increased ERK5 activation in addition to prolonged ERK2 
phosphorylation.  Proliferation studies were also performed in PC3 cells, the results of 
which support published data that ERK1 acts as a negative regulator and ERK2 as a 
positive regulator of cell proliferation. 
ERK5 has been shown to regulate the activity of several transcription factors and recent 
evidence suggests that ERK5 may be heat shock protein (HSP) 90 dependent. To further 
investigate the ERK5 signalling network and its interacting proteins, I performed mass 
spectrometry-based quantitative proteomics using SILAC labelled cells.  Results from this 
study support the theory that HSP90 does associate with ERK5 however contrary to 
published data my results show that it is not involved in ERK5 activation.   
   3
Our results validate the importance of the MEK5-ERK5 signalling pathway as a potential 
target for therapy in prostate cancer and highlight a novel functional and biochemical 
relationship between ERK1 and HSP 90 with ERK5 signalling.   
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1 Introduction 
1.1 Prostate  Cancer 
1.1.1  Epidemiology of disease 
Prostate cancer is the most commonly diagnosed cancer and the second commonest 
cause of cancer related death in men in the western world (1) .    In 2005, 34,302 new cases 
of prostate cancer were diagnosed in the UK (2).  A significant increase in incidence has 
been reported since the 1980’s due to an increase in rates of transurethral resection of the 
prostate (TURP) and prostate specific antigen (PSA) testing (3).   
1.1.2  Aetiology of prostate cancer 
There is currently no modifiable risk factor identified for prostate cancer however 
three established risk factors have been found: age, family history and ethnicity.  The 
incidence of prostate cancer increases with age and over 70% of patients with prostate 
cancer are over the age of 65 years (3).  With an aging society, it is therefore inevitable that 
prostate cancer will become an increasing health burden in years to come.   
A family history of prostate cancer is also recognised as a strong risk factor for the 
disease.  Familial forms of prostate cancer, which are those in which at least 2 first degree 
relatives are affected accounts for approximately 20% of cases and genetic susceptibility 
has been shown to play a more significant role in younger patients (4).   
The worldwide variation in incidence rates suggests that the risk of developing 
prostate cancer is affected by ethnicity.  In the UK, black Caribbean and black African men 
have 2-3 times the risk of white men in developing or dying from prostate cancer while 
Asian men generally have a lower risk (5).  Migration studies suggest however that 
lifestyle factors must also play an important role as men who move from a low-risk to a 
higher-risk country show an increase in incidence (6). 
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1.1.3  Pathological Staging and Grading 
The majority of prostate cancers are adenocarcinomas and mainly occur in the 
peripheral zone of the prostate.  Prostate cancers are classified using the tumour-nodes-
metastasis (TNM) staging system (Table I).  This system evaluates the size of the tumour, 
the extent of involved lymph nodes and the presence of any metastasis.  The gleason 
grading system is used to grade prostate tumours and together with TNM staging is used to 
predict prognosis and guide patient management.  A score of 1-5 is given to the cancer 
based on its microscopic appearance.  A higher score indicates a more aggressive tumour 
with a worse prognosis.  A gleason grade is given to the most common tumour and a 
second score given to the next most common tumour.  These grades are added together to 
give a gleason sum score which is used to guide treatment options for men with prostate 
cancer. 
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TABLE I:  The TNM grading system 
Evaluation of the (primary) tumour ‘T’ 
 
•  TX: cannot evaluate the primary tumor  
•  T0: no evidence of tumor  
•  T1: tumor present, but not detectable clinically or with imaging  
o  T1a: tumor was incidentally found in less than 5% of prostate tissue resected 
(for other reasons)  
o  T1b: tumor was incidentally found in greater than 5% of prostate tissue 
resected  
o  T1c: tumor was found in a needle biopsy performed due to an elevated serum 
PSA  
•  T2: the tumor can be felt (palpated) on examination, but has not spread outside the  
prostate  
o  T2a: the tumor is in half or less than half of one of the prostate gland's two 
lobes  
o  T2b: the tumor is in more than half of one lobe, but not both  
o  T2c: the tumor is in both lobes  
•  T3: the tumor has spread through the prostatic capsule (if it is only part-way through, 
it is still T2)  
o  T3a: the tumor has spread through the capsule on one or both sides  
o  T3b: the tumor has invaded one or both seminal vesicles  
•  T4: the tumor has invaded other nearby structures  
 
Evaulation of the regional lymph nodes ‘N’ 
•  NX: cannot evaluate the regional lymph nodes  
•  N0: there has been no spread to the regional lymph nodes  
•  N1: there has been spread to the regional lymph nodes 
 
Evaulation of distant metastasis ‘M’ 
•  MX: cannot evaluate distant metastasis  
•  M0: there is no distant metastasis  
•  M1: there is distant metastasis  
o  M1a: the cancer has spread to lymph nodes beyond the regional ones  
o  M1b: the cancer has spread to bone   
o  M1c: the cancer has spread to other sites (regardless of bone involvement) 
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1.1.4 Clinical  management 
Treatment options for men diagnosed with prostate cancer depend on a number of 
factors including patient performance status, disease status (tumour grade and stage) and 
social factors (Table II).  Prostate cancer diagnosed at an early stage (or when organ 
confined) are potentially curable and various options are available for these patients.   
Watchful waiting may be considered if the patient has low grade, small volume disease and 
a life expectancy of less than 10 years.  Follow up for these patients will focus on serial 
serum PSA measurements and clinical symptoms and if disease progression is evident, the 
patient can be considered for intervention such as medical treatment.  
Active surveillance is offered to patients who are found to have prostate cancer, 
which is thought to be clinically insignificant, and at low risk of progression.  Active 
surveillance involves PSA measurements and digital rectal examinations (DRE) every 3 
months with repeat prostate biopsies to re-grade the cancer 12-24 months following initial 
diagnosis or if significant changes are found in the PSA level or DRE.  If these show that 
the cancer is progressing then treatment with curative intent will be recommended, in most 
cases being either surgery or radiotherapy.  However, the optimal protocol for active 
surveillance remains to be validated in a prospective trial. 
Radical treatment is offered for patients who have localised disease and good life 
expectancy.  Surgical options include retropubic radical prostatectomy (RRP) with 
laparoscopic or robotic-assisted approaches gaining popularity in recent years.  Whether 
these novel techniques will translate into better outcome await formal assessment.   
Conformal external beam radiotherapy (EBRT) or brachytherapy represent radiation based 
curative options for patients with early disease. 
Androgens are the primary regulators of prostate cancer cell growth and 
differentiation and prostate cancer is often androgen dependent, with the majority 
regressing following initial androgen ablation treatment.  Current medical therapy for 
patients diagnosed with prostate cancer includes anti-androgens and gonadotrophin-
releasing hormone (GnRH) analogues.  Anti-androgens block the effect of androgens 
directly on target cells by inhibiting their binding to the androgen receptor (AR).  GnRH 
analogues work at the level of the pituitary with continued administration producing down 
regulation of GnRH receptors thereby reducing the release of gonadotophins which leads 
to inhibition of androgen production.  Medical therapy is a treatment option either alone or 
in addition to radiotherapy in patients with locally advanced disease.  Hormone deprivation   21
is the treatment of choice in patients with metastatic disease most often in the form of 
medical therapy but some patients may be offered a subcapsular orchidectomy which has 
the advantage of achieving rapid androgen ablation.  
Unfortunately, approximately 20% of patients do not show a favourable response, 
and even among the responders, there is an 80% risk of relapse at a median period of 24 
months following hormone manipulation.  Patients are diagnosed with castration resistant 
prostate cancer (CRPC) when they show evidence of a rising PSA (PSA > or = 2ng/ml 
above nadir) (7).  Treatment for these patients is limited.  Secondary (and tertiary) 
hormonal manipulation such as discontinuation of steroidal or nonsteroidal hormones or 
the addition of anti-androgens, oestrogens, glucocorticoids or enzymatic inhibitors of the 
adrenal androgen synthesis pathway may produce a transient biochemical response.  In 
addition, patients with clinically localised disease receiving radical treatment have a 
significant failure rate over 5-10 years period of follow up (reported rates of 23% post RRP 
and 63% post EBRT) (8). 
Docetaxel has recently been licensed for use in combination with corticosteroid 
therapy in men with metastatic CRPC following the results of two Phase III trials(9;10).  
The mean survival benefit in these studies only measured 2 and 2.5 months respectively 
and timing of this treatment remains controversial.  Trials are now focusing on improving 
the efficacy of docetaxel by combining it with novel biological agents.  In addition, there is 
now an increasing interest in testing the efficacy of novel agents in hormone naive disease, 
which may result in better overall response and outcome.  The STAMPEDE (Systemic 
Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy) study, a 
5 arm randomised controlled trial, is one example, aimed to recruit patients with high-risk 
prostate cancer.  This large multicentre trial examines the efficacy of combining androgen 
ablation therapy with a number of agents including docetaxel, zoledronic acid 
(bisphosphonate) and celecoxib (cox-2 inhibitor) (11). 
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TABLE II:  Treatment options for prostate cancer                                                                   
(NICE clinical guideline 58) 
Early stage (or organ confined disease,T1/2N0M0) 
 
Conservative managment 
•   Watchful waiting - Suitable for patients with low grade, small volume disease and life 
expectancy <10years.  Treat if rise in PSA.  
 
•  Active surveillance – If disease considered clinically insignificant and at low risk of 
progression.  Involves 3 monthly PSA check and DRE.  Repeat biopsy at 12 months.  
 
 
Radical treatment 
•  Radiotherapy – External Beam Conformal Radiotherapy or interstitial brachytherapy  
 
•  Radical prostatectomy – retropubic, laparoscopic or robotic assisted prostatectomy  
 
•  Other experimental methods yet to be validated in formal randomised controlled trials 
include Cryotherapy, High Intensity Focused Ultrasound therapy (HIFU) 
 
 
Locally advanced (T3N0M0) 
 
•  Androgen Deprivation Therapy (ADT) – GnRH analogue and/or anti androgen  
 
•  Radiotherapy +/- ADT  
 
Metastatic disease 
 
•  ADT  
 
•  Subcapsular orchidectomy  
 
Castration Resistant Prostate Cancer (CRPC) 
 
•  Second or third line hormonal manipulation – Discontinue steroidal or nonsteroidal 
hormones or addition of antiandrogen, oestrogen, glucocorticoid or enzymatic inhibitor 
of adrenal androgen synthesis  
 
•  If metastatic disease, consider chemotherapy (docetaxel and prednisolone)  
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1.2  Androgen receptor signalling in prostate cancer 
The androgen receptor (AR) regulates prostate organogenesis as well as the 
development and progression of prostate cancer.  Androgen deprivation leads to apoptosis 
in a proportion of prostate cancer cells and those which do survive arrest in the G1 phase 
of the cell cycle (12).  However, as prostate cancer progresses cells evolve and develop 
mechanisms to survive in an androgen depleted environment.  This progression is 
recognised to involve an active AR and various mechanisms in which this altered 
signalling is implicated in the transition to hormone (or castrate) resistance have been 
described (13). 
Reactivation (or the continued activation) of the AR and AR responsive pathways 
allow tumours to develop a hormone independent phenotype through altered AR 
sensitivity, AR amplification and AR mutations (14;15).  Mutations in the AR can lead to 
activation by non-adrogenic steroid molecules and anti-androgens.  This may explain why 
10-30% of patients who develop resistant cancer following treatment with anti-androgens 
may show a paradoxical drop in PSA levels when the particular anti-androgen is 
discontinued (16).   
Circulating serum androgen levels are not completely eliminated with hormone 
deprivation therapy (HDT).  While serum testosterone levels are significantly reduced, 
serum levels of adrenal androgens remain unaffected.  Intraprostatic androgens are also 
reduced sufficiently with HDT to induce a response in untreated prostate cancer cells.  It is 
interesting to note that CRPC tumours have increased endogenous synthesis of androgens 
(17), along with upregulation of the enzymes required for steroidogenesis (18;19).  Hence, 
tumour cells, particularly in castrate resistant disease, with their increased intracrine 
androgenic production, may be responsible for tumour progression despite low serum 
androgen levels. 
Growth factors and their signalling cascades such as HER2, IGF-1, and EGF can 
also activate the AR via the PI3K/Akt and MAPK pathways and reduce or negate the need 
for ligand binding (Figure 1.1).  Overexpression of these coactivators in prostate cancer 
leads to indirect activation of the AR and many agents currently in trial for use in CRPC 
target these signalling pathways.  
In order for CRPC to establish, prostate cancer cells must also overcome the 
apoptotic effects of androgen depletion.  The induction of AR independent pathways   24
including receptor tyrosine kinase (RTK) mediated networks allows prostate cancer cells to 
survive via the upregulation of anti-apoptotic proteins such as survivin and bcl-2. 
Genetic alterations are important in the metastatic progression of tumour cells.  In 
addition to these changes alterations in the tumour microenvironment are required to allow 
local growth and invasion as well as distant metastasis to develop.  It has been suggested 
that cells within the stroma secrete a wide range of growth factors, extracellular matrices, 
metalloproteinases and/or angiogenic molecules to promote prostate cancer cells into a 
tumorigenic and invasive phenotype.  It is now thought that a more efficacious method of 
treatment may involve targeting both the tumour and stroma, blocking both the tumour 
cells’ proliferative ability and also the required support from the microenvironment. 
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FIGURE 1.1  Receptor tyrosine kinase signalling and the androgen receptor 
 
In castration resistant prostate cancer (CRPC), androgen receptor remains functional and 
is thought to significantly contribute to cancer progression.  A number of mechanisms of 
AR activation in an androgen depleted environment have been described (see text for 
further details) and cross talk from receptor tyrosine kinase signalling pathways plays an 
important role in CRPC.  (Abbreviations:  AR - androgen receptor; DHT – 
dihydrotestosterone; EGFR - epidermal growth factor receptor; FGF / R- fibroblast 
growth factor receptor; IGF-1 / -1R - Type I insulin-like growth factor / receptor; MAPK -  
mitogen activated protein kinase; MEK - MAP kinase kinase ; PIP2 – phosphatidyl-
inositol biphosphate; PIP3 - phosphatidylinositol triphoshate; PI3K - phosphoinositide 3-
kinase; RTK -  receptor tyrosine kinase) 
The symbol   signifies the development and evaluation of key inhibitors in clinical trials, 
including PI3 kinase inhibitors (CCI-779, RAD001); EGFR (Erlotinib, Gefitinib, 
Cetuximab); EGFR and HER2 dual inhibitor (Lapatinib); IGF-1R inhibitor (A12, CP-
751,871); Androgen receptor inhibitor (MDV-3100, BMS-641988); 5α-reductase inhibitor 
(Dutasteride); apoptosis/survivin (YM155); CYP17 (Abiraterone, to reduce adrenal and 
intra-tumour androgen biogenesis)(see Table III and text for detail). 
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1.3  Aberrant signalling pathways involved in prostate carcinogenesis 
Abnormal signalling is thought to mediate many of the tumourigenic activities 
involved in cancer development and progression; discoveries in this field offer potential 
targets for new drug development.  The progression of epithelial prostate cells from a 
normal differentiated state in which proliferation and apoptosis are tightly balanced to a 
malignant state involves a combination of events resulting in the activation of oncogenes in 
addition to the loss of tumour suppressor genes, which critically control aspects of the 
hallmarks/phenotypes of cancer (Table III) (20).  Many signalling pathways have been 
found to be important in prostate carcinogenesis and in recent years targeted therapy has 
emerged as a key focus for prostate cancer research.  
RTKs for growth factors are essential for the transduction of extracellular signals to 
their cytoplasmic effectors.  RTKs activate several pathways controlling cell proliferation 
and differentiation as well as migration and apoptosis.  In normal cells the activity of RTKs 
is tightly regulated; however in cancer constitutive activation of RTKs is essential for 
maintaining the malignant phenotype.   
Tumour suppressor genes (TSG) critically regulate the cell cycle, apoptosis, DNA 
repair, senescence and angiogenesis.  Deranged TSG function in carcinogenesis can result 
from two distinct mechanisms. The function of a TSG can be impaired by (1) mutation or 
deletion abnormalities, or (2) binding to a regulatory protein which can either inhibit the 
function or impair the stability of the target TSG. TSGs such as p53 and PTEN are 
important in prostate carcinogenesis (see section 1.7). 
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TABLE III: Hallmarks of cancer and the role of novel agents in prostate cancer  
Hallmark of cancer   Example of targeted therapy  
Self-sufficiency in growth factors  Erlotinib (EGFR inhibitor)  
Evading apoptosis   YM155 (Inhibitor of Survivin)  
Tissue invasion and metastasis   Dasatinib (Src inhibitor)  
Sustained angiogenesis   Bevacizumab (VEGF inhibitor)  
Increased cell metabolism   CCI-779 (mTOR inhibitor)  
 
Table III illustrates examples of novel agents that target various phenotypic hallmarks of 
cancer.  Many targeted therapies however act on a number of these phenotypes e.g. 
Atrasentan (ET-A receptor antagonist) is thought to affect the following functions: evading 
apoptosis, tissue invasion and metastasis and sustained angiogenesis.  Androgen ablation 
therapy in prostate cancer also affects distinct aspects of carcinogenesis including 
metabolism, apoptosis and growth.  
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1.4  Molecular mechanisms of targeted therapy 
Different mechanisms have been used to target molecular signalling in cancer with 
inhibition of RTK signalling offering the most success to date.  Currently two classes of 
compounds are commonly used to inhibit RTK activation: small molecule tyrosine kinase 
inhibitors (TKI) and monoclonal antibodies (mAb).  While both inhibit RTK signalling, 
they have distinct targeted epitopes and mechanisms of action (21).  ATP-dependent TKIs 
can translocate through plasma membranes and interact with the cytoplasmic domain of 
cell surface receptors and intracellular signalling molecules.  They competitively bind to 
the ATP-binding site in the catalytic domain of the receptor, inhibiting 
autophosphorylation and the activation of intracellular signal transducers. 
In contrast mAbs can only act on molecules that are expressed on the cell surface or 
secreted, as they are unable to pass through the cell membrane. Different ways mAbs 
inhibit RTK signalling are suggested which can be further separated into direct and indirect 
mechanisms.  Direct action includes the following: blocking the function of target 
signalling molecules or receptors, stimulating function which results in apoptosis and 
targeting function by conjugating mAbs with toxins, radioisotopes or cytokines.  The 
indirect action described involves the binding of immunoglobulins to the surface of the 
cells mediating complement-dependent cytotoxicity and antibody-dependent cellular 
cytotoxicity, both of which eventually lead to cancer cell death. 
TKIs tend to offer the most efficient method of targeted therapy as they block the 
kinase activity of the targeted receptor, significantly inhibiting the activation of 
downstream signalling.  Depending on the selectivity of the candidate compounds, they 
may act as multi target agents as they are prone to bind to different RTKs due to the 
structure of the ATP-binding pocket being highly conserved within the tyrosine kinase 
family.  In contrast mAbs tend to be specific inhibitors and have been shown to only offer 
modest antitumour activity when used alone with more significant effects being noted 
when combined with chemotherapy.   
In addition to TKIs and mAbs, other types of targeted therapy have also been used 
successfully in preclinical studies.  Antisense oligonucleotides target specific sequences in 
the mRNA of interest, implicated to be a causative factor for carcinogenesis, thus 
inhibiting its expression and protein translation.  Antisense oligonucleotides are currently 
in clinical trial as anti-cancer agents however to date none have been approved for use.   29
1.5  Molecular targeted therapy – examples of recent success in selected tumour 
types 
1.5.1  BCR-ABL tyrosine kinase in Chronic Myeloid Leukaemia 
Chronic Myeloid Leukaemia (CML) is a myeloproliferative disease which is 
characterised by the expansion of a clone of haemopoietic cells that carry the Philadelphia 
chromosome (Ph).  The Ph chromosome is due to a reciprocal translocation between the 
long arms of chromosomes 9 and 22.  This translocation results in a novel fusion gene 
BCR-ABL, which encodes a constitutively active protein tyrosine kinase.  The treatment of 
CML has been revolutionised since the discovery of a relatively specific inhibitor of the 
BCR-ABL tyrosine kinase, imatinib (Glivec).  Treatment with this small molecule 
inhibitor in patients diagnosed with chronic phase CML results in high rates of complete 
cytogenetic remission (>87%) and molecular remissions with low or undetectable amounts 
of BCR-ABL transcripts (22).  Imatinib is now established as standard therapy for this 
patient group taking over from its predecessor interferon-α.  Results from a 5 year follow 
up study were recently published confirming durable responses in patients with chronic-
phase CML (23).  This study followed patients who had been initially treated with imatinib 
and then were either continued on treatment with this tyrosine kinase inhibitor or given 
interferon-α and cytarabine.  Patients treated with imatinib had high rates of cytogenetic 
response and the estimated overall survival at 60 months was 89% compared to previous 
studies of interferon-α plus cytarabine with survival rates around 65% (24). 
Approximately 10% of patients treated with imatinib will subsequently develop 
resistance, and between 50-90% of these cases are associated with mutations in the kinase 
domain of BCR-ABL (25).  Over-expression of Src related kinases has also recently been 
implicated in treatment resistance, which may explain the efficacy of some second 
generation BCR-ABL inhibitors such as nilotinib and dasatinib in imatinib relapsed disease 
(26;27).  Novel therapies continue to be developed as advances in the molecular 
understanding of disease progression in CML emerge. 
 
 
 
 
 
   30
1.5.2 Trastuzumab  (Herceptin) in Breast Cancer 
Another example of successful targeted therapy is HER2 mediated therapy in breast 
cancer.  The human epidermal growth factor receptors (HER), namely HER 1-4, are a 
group of four transmembrane tyrosine kinase receptors that normally regulate cell growth 
and survival.  HER2 gene amplification and protein overexpression is found in 20-30% of 
invasive breast cancers (28).  HER2 positive breast cancer patients in general have 
decreased overall survival and differential responses to standard chemotherapeutic and 
hormonal regimes (29).  
Trastuzumab (Herceptin) is a monoclonal antibody to the HER2 ectoderm and has 
been shown to significantly improve the outcome for HER2 positive breast cancer patients.  
It acts by binding to the extracellular juxtamembrane domain of HER2, resulting in 
inhibition of proliferation and reduced survival of HER2 dependent tumours.  Trastuzumab 
has been shown to significantly improve patient outcome in both HER-2 positive breast 
cancer of both early stage and metastatic stage (30;31).  Trastuzumab is recommended as 
treatment for women with early-stage HER2 positive breast cancer following surgery, 
chemotherapy (neoadjuvant or adjuvant) and radiotherapy (32). It is also recommended 
that all patients who have HER2 positive advanced breast cancer be considered for 
treatment with trastuzumab either as monotherapy (if metastatic and had previous 
chemotherapy) or in combination with chemotherapy and/or hormonal agents (33;34).  
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1.6  Target signalling in prostate cancer 
Despite the success of targeted therapy in other tumour types and the improved 
understanding of abnormal signalling activities in prostate carcinogenesis, none of the 
novel agents studied so far have shown adequate efficacy to justify their routine use in 
prostate cancer.  Research and drug development programmes therefore continue to strive 
for a better understanding of the signalling network involved and in order to develop a 
more efficacious treatment regime. 
 
1.6.1 PI3K  Pathway 
The phosphoinositide 3-kinase pathway has been shown to regulate multiple 
cellular events in prostate cancer.  PI3K activation results in the catalytic conversion of 
phosphatidylinositol biphosphate (PIP2) to phosphatidylinositol triphoshate (PIP3) which 
in turn activates Akt.  Mammalian target of rapamycin (mTOR) is a serine/threonine kinase 
that regulates cell growth and is involved in tumourigenesis.  Akt phosphorylates and 
activates mTOR to enhance cell growth.  PTEN is a tumour suppressor gene which 
negatively regulates the PI3K pathway. In prostate cancer loss of PTEN and/or Akt 
activation is coupled with high Gleason score (towards an undifferentiated phenotype), an 
advanced clinical stage and poorer prognosis (35;36).  The PI3K pathway is also associated 
with hormone resistance and chemotherapeutic insensitivity.  High levels of phosphoAkt 
immunostaining have been shown to be predictive of biochemical recurrence and 
phosphoAkt-1 expression has been suggested to be an independent prognostic marker of 
biochemical recurrence-free survival in a subgroup analysis of patients with Gleason score 
of 6 and 7 (n=488 p=0.0012) (35).  In vitro studies have shown that PTEN loss is 
associated with increased resistance to both doxorubicin and paclitaxel and treatment with 
a PI3K inhibitor reverses this chemoresistance in prostate cancer cells (37). 
Inhibition of PI3K signalling has been studied in vitro using two small molecule 
inhibitors which have been available for some time, namely wortmannin and LY24002.  
Both of these have demonstrated antitumour effects in prostate cancer cell lines (38), 
however both have a relatively broad spectrum of activity inhibiting other kinases related 
to PI3K such as ATM and ATR.  There are a large family of PI3Ks including the four class 
I lipid kinase isoforms p110α, p110β, p110δ and p110γ.  Each of these isoforms is thought 
to have an individual role in cell behaviour.  Of note, p110α protein has been found to be 
overexpressed and mutated in a number of solid tumours including prostate cancer (39).  
Targeting the p110α isoform in cancer is therefore an attractive strategy in drug   32
development for prostate cancer.  PI-103 inhibits the PI3K pathway at multiple sites 
including the p110α isoform as well as mTOR-raptor complex (mTORC1) and mTORC2.  
This dual p110α/mTOR inhibitor has been shown in PC3 cells to reduce proliferation and 
invasion and has significant anti-tumour activity in xenograft tumour models (40).  Formal 
published results on the use of PI-103 in clinical trial are awaited. 
           Inhibition of Akt is another important strategy for drug development.  A number of 
small molecule inhibitors including A-443654, Akt-I-1 and Akt-I-2 have been tested in 
vitro and in preclinical in vivo models for their anti-tumour effects with promising findings 
(41).  Future investigations of these agents in the clinic will inform us of their potential as 
novel therapies. 
PTEN inactivation results in deregulated signalling through the mTOR pathway.  
mTOR is the target of the antibiotic rapamycin which is used as an immunosuppressant 
following renal transplantation.  At present there are three rapamycin derivatives in 
development: temsirolimus (CCI-779), everolimus (RAD001) and deforolimus (AP23573).  
Both CCI-779 and RAD001 have been shown to have beneficial effects in vivo.  
Transgenic mice with activated Akt or PTEN deficiencies have decreased tumour growth 
when treated with CC1-779 (42). Similarly, RAD001 has been shown to reverse prostate 
neoplastic phenotypes in mice expressing human Akt (43).  AP23573 has been shown to 
have promising antitumour activity in sarcoma and selected haematological malignancies.  
A phase II trial using CCI-779 for patients with CRPC has recently finished recruiting 
however to date no results are available. Both RAD001 and AP23573 and are currently 
being assessed in phase II clinical studies. 
 
1.6.2  Src Family Kinase 
The Src family kinases (SFK) are a group of non-receptor protein tyrosine kinases 
which are involved in tumour adhesion, motility, invasion and angiogenesis.  SFK 
members Src and Lyn are highly expressed in prostate cancer cell lines as well as in the 
majority of prostate cancer specimens (44;45).  Src signalling is involved in androgen 
induced proliferation of prostate cancer cells and recently it has been suggested that Src is 
involved in the transition to androgen independent growth (46).  Bone metastases occur in 
the majority of prostate cancer patients with advanced disease.  Src inhibition in vivo has 
shown reduced morbidity, lethality and incidence of bone metastases in breast cancer 
mouse models (47).  Therefore a small molecule inhibitor targeting Src may have the   33
therapeutic advantage in prostate cancer in minimising morbidity associated with bone 
metastases and possibly improving survival outcome. 
Dasatinib is a SFK/Abl inhibitor and has in vitro activity in prostate cancer cells.  
Proliferation, invasion and migration have been shown to be reduced when DU145 cells 
were pretreated with dasatinib (44).  A significant reduction in tumour growth and 
metastases has also been demonstrated when dasatinib was used in prostate cancer 
xenograft models.  Phase II studies are currently ongoing to assess dasatinib in CRPC as 
well as combination therapy with docetaxel in metastatic disease.  Results from phase II 
trials in imatinib-resistant CML with dasatinib have shown minimal toxicity thus reducing 
concerns that Src inhibition may suppress multiple pathways and be associated with high 
levels of adverse effects (48;49). 
AZD-0530, another Src inhibitor, has been shown to inhibit the growth of prostate 
cell lines and suppress migration in PC3 and DU145 cells (50).  It also suppressed the 
growth and metastasis of androgen-independent LNCaP cells in vivo (51).  Studies in 
healthy volunteers have found only mild side effects with AZD-0530 and a phase II trial in 
CRPC has recently started.  Finally Bosutinib, another Src/Abl inhibitor, which has shown 
in vitro and in vivo activity in models of CML (52), colon cancer (53)  and breast cancer 
(54); no published results are available for prostate cancer to date.   
 
1.6.3  The ErbB receptor family 
The ErbB family of receptor tyrosine kinases include epidermal growth factor 
receptor (EGFR/ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4).  Both EGFR 
and HER2 have critical roles in cell growth, differentiation and the motility of normal and 
cancer cells through the activation of downstream signalling pathways such as the MAPK 
and PI3K/Akt pathway.  EGFR is highly expressed in primary prostate cancer and 
associated metastases (55).  Overexpression of EGFR is associated with poor prognosis 
(56) and the transition of androgen sensitive disease to androgen independence (57).   
Current anti-EGFR therapies include both TKIs and mAb therapy. Small molecule 
TKIs have been the most successful method to date in EGFR targeting with Erlotinib 
(Tarceva) approved for use in the treatment of pancreatic and non-small cell lung cancer 
(NSCLC) after failure of at least one prior chemotherapy regimen (58;59).  Progression 
free survival in NSCLC however is only improved by 2 months with a reported response 
rate of 8.9 % (59). Methods have been investigated to improve patient selection with both 
EGFR mutation and an increase in EGFR copy number recognised as biomarkers for   34
favourable response to Erlotinib in NSCLC (60;61).  Erlotinib has also been studied in 
CRPC in combination with docetaxel.  Results of a phase II study demonstrated no 
beneficial anti-cancer activity with erlotinib added to docetaxel monotherapy (62).   
However, the pre-treatment EGFR status was not available.  Further studies of erlotinib in 
non-metastatic prostate cancer and chemotherapy naïve disease are ongoing.  EGFR 
mutation and amplification of the EGFR gene have been shown to occur frequently in 
advanced prostate cancer however unlike NSCLC there are currently no stratified studies 
to include either EGFR mutation or gene amplification to improve patient selection for 
treatment with anti-EGFR therapy (63).  Erlotinib combined with bevacizumab (vascular 
endothelial growth factor inhibitor) has been shown in NSCLC to increase progression free 
survival and this combination regime is currently being tested in prostate cancer patients 
following radical prostatectomy (64).  
Gefitinib (Iressa) is another orally active EGFR TKI which has been shown to have 
antiproliferative activity in prostate cancer cell lines(65).  EGFR suppression with gefinitib 
results in significant growth inhibition in PC3 xenografts  (66) and has been shown to 
reduce the incidence of prostate cancer metastasis in nude mice (67).  Phase I data of 
gefitinib monotherapy in a range of solid tumours showed promising antitumour activity 
(68); however phase II results in non-metastatic CRPC reported no positive response 
(69;70).  EGFR status was assessed in a subset of patients where moderate-strong staining 
was noted in 12 out of 16 cases (69).  There was no correlation between EGFR expression 
and PSA decline or time to progression suggesting that in prostate cancer EGFR 
overexpression is not indicative of response to gefitinib. 
PD168393 also selectively inhibits EGFR and it has been shown to sensitise 
prostate cancer cells to the cytotoxic activity of paclitaxel (71).  There is currently no in 
vivo or clinical evidence of this small molecule inhibitors effect in prostate cancer. 
A number of anti-EGFR monoclonal antibodies have been introduced over recent 
years with cetuximab being approved for use in patients with colorectal cancer refractory 
or intolerant to irinotecan and in patients with squamous cell carcinoma of the head and 
neck (72;73).  Phase I results of panitumumab, another EGFR mAb in advanced solid 
tumours showed treatment was well tolerated, but patients with prostate cancer showed 
very limited response (74).  Patients with CRPC are currently being recruited for phase II 
trials of cetuximab treatment combined with either docetaxel or mitoxantrone.  Taken 
together, while EGFR inhibitors, namely Erlotinib, Gefitinib and PD168393, all target the 
kinase domain of EGFR and have encouraging data to support their clinical use in a 
number of tumour types, it is disappointing that similar efficacy has not been seen in   35
prostate cancer.  Many factors may contribute to this (see Drug development against 
implicated biological targets, Section 6.1).  The lack of stratification among patients 
according to their EGFR status (namely expression level, mutation and amplification), as 
an indicator of the significance of abnormal EGFR function as a driving event in prostate 
carcinogenesis, may partly explain the negative results in a number of trials.  Future studies 
should focus on targeted assessment of these novel agents in prostate cancer sufferers with 
defined genetic (or epi-genetic) lesions involving EGFR. 
Amplification of the HER2 gene and/or overexpression of the HER2 protein occurs 
in 20-30% breast cancer patients and is associated with an unfavourable outcome (28;29).  
In contrast, the impact of HER2 in prostate cancer is much less clear, with HER2 
overexpression and/or amplification being identified much less frequently in prostate 
cancer (75).  There is also no strong consensus regarding its impact in clinical outcome.  
This may account for the negative findings in a phase II study using trastuzumab 
(herceptin) in CRPC (76), which did not support a phase III trial of herceptin. 
HER2 is an orphan receptor and functions as a coreceptor.  Recent work has shown 
that HER2/HER3 dimerization and activation may stimulate androgen-receptor mediated 
signalling in an androgen depleted environment (77).  Agents, which may target HER2 
dimerisation signalling, include pertuzumab and lapatinib.  Pertuzumab is a monoclonal 
antibody which inhibits HER2 dimerisation with other HER family members including 
EGFR, HER3 and HER4 (78).  Unfortunately, a phase II trial of pertuzumab in CRPC 
showed no PSA response, while the treatment was well tolerated (79).   A phase I study of 
docetaxal and pertuzumab in solid tumours shows promising results in the CRPC patients 
with stable disease observed in half of the patients after 4 cycles (12 weeks) of treatment 
(80).  The dual EGFR/HER2 TKI lapatinib is more potent than gefitinib to inhibiting 
proliferation (81).  A phase II trial of lapatinib in recurrent or metastatic prostate cancer is 
currently being evaluated.  
Despite the infrequency of HER2 overexpression, the kinase activity of this 
receptor is strongly implicated in the progression to CRPC.  Tyrosine phosphorylation of 
HER2 has been shown to play a key role in regulating androgen mediated proliferation in 
human prostate cancer cells (82).  Furthermore the inhibition of HER2 kinase activity by 
lapatinib impairs AR transcriptional activity (83).  The discrepancy for the role of HER2 
(and EGFR) between in vitro analysis and clinical studies requires attention in future 
translational trials to incorporate assessment of target (including expression level, mutation 
and amplification status) and clinical evaluation of efficacy along with validation of drug 
induced effects on the target.   36
HER3 plays an essential role in EGFR and HER2 driven tumourigenesis.  This 
ErbB member is also known to have a central role in mediating PI3K/Akt signalling.  In 
contrast to other ErbB receptors, HER3 is kinase inactive and is not a direct target of 
tyrosine kinase inhibitors.  It is suggested that HER3 may be responsible for the drug 
resistance, which has been observed with EGFR and HER2 inhibitors, and therefore 
research is currently focussing on HER3 as a new target for anticancer therapies.   
 
1.6.4  The Fibroblast growth factor receptor (FGFR) family 
Fibroblast growth factors (FGF) including FGF1, FGF2, FGF6, FGF8 and FGF17 
are all expressed at increased levels in prostate cancer (84-89).  FGFs signal through 
fibroblast growth factor receptors (FGFR1-4) activation, which leads to downstream 
signalling through multiple pathways including the MAPK and PI3K pathways.  FGFR4 is 
overexpressed in prostate cancer with strong expression associated with high grade disease 
and decreased survival (90).  FGFR1 and 2 also show overexpression in prostate cancer 
when compared to BPH; however FGFR2 shows no correlation with tumour grade or stage 
(91).  Recent transgenic models further validate the role of FGFR signalling as key to 
prostate carcinogenesis(92;93). 
Over recent years work has focussed on selective targeting of the receptors 
involved in FGF signalling as a novel therapeutic approach in prostate cancer.  FGFR 
inhibition using siRNA to target FGFR4 in prostate cancer cells shows suppression of 
proliferation and invasion (91).  SU5402 potently blocks FGFR1 tyrosine kinase activity 
while weakly inhibiting PDGF receptor function   In vivo SU5402 has been shown to 
decrease xenograft tumour growth and suppress PSA and promotrilysin expression in a 
prostate cancer model (94).  To date there are no published results of a FGFR inhibitor in a 
clinical trial.   
 
1.6.5  Type I insulin-like growth factor receptor 
Type I insulin-like growth factor receptor (IGF-1R) is activated by insulin-like 
growth factor I or II (IGF-I/II).  The IGF-1R is crucial in maintaining the malignant 
phenotype with evidence showing its role in proliferation, angiogenesis and apoptosis.   
IGF-1R activation is ligand dependent and once activated IGF-1R recruits and 
phosphorylates adaptor proteins, which serve as docking sites for other signalling 
molecules.  This results in activation of intracellular signalling pathways including PI3K 
and ERK1/2 of the MAPK pathway.     37
IGF-1R is significantly up-regulated in prostate cancer when compared to benign 
prostatic epithelium (95) and in vitro work has shown that IGF-1R overexpression is 
associated with androgen independent antiapoptotic and promitotic signalling, processes 
which drive prostate cancer disease progression (96).  
Several approaches have been used to inhibit IGF-1R signalling via reduction or 
neutralisation of circulating IGF-1 or by inhibition of IGF-1R activation. At present the 
most promising method is to use antibodies against IGF-1R.   The human antibody A12 
has been used in prostate xenograft tumours to study the beneficial effects of blocking 
IGF-1R signalling following castration (97).  IGF-1R inhibition enhanced the effect of 
castration and prolonged tumour-specific survival.  Combination treatment was also 
associated with a decrease in AR signalling and nuclear AR localisation.  These results 
suggest that IGF-1R inhibition in conjunction with androgen ablation enhances the 
inhibition of signalling through the AR, which remains important even in CRPC.  IGF-1R 
inhibition in xenografts has also been shown to potentiate the activity of cytotoxics (98).  
A12 and CP-751,871 another monoclonal anti-IGF-1R antibody are currently in phase II 
trial to test their efficacy in combination with docetaxel and prednisone in the treatment of 
CRPC. 
Both IGF-1 and IGF-binding protein-3 (IGFBP-3) have been reported to be 
associated with an increased risk of prostate cancer.  Conflicting evidence for both 
biomarkers has been published however with recent evidence showing no observed 
association for IGFBP-3 (99;100).    
 
1.6.6  Heat Shock Proteins 
Heat shock proteins (HSP) are cellular chaperones involved in the regulation and 
stabilisation of a number of key signal transduction proteins including MAPK, Akt, AR 
and Src kinases (101).   
It has been suggested that HSP27 may be at the centre of many pathways involved 
in the regulation of the response of a cell to treatment induced stress and targeting it may 
lead to silencing of multiple survival pathways.  Apoptosis resistance is associated with 
increased expression of multiple HSPs and small HSP such as HSP27 have been found to 
be important chaperones which protect cancer cells against apoptosis (102).  Cytotoxic 
treatments such as chemotherapy and radiotherapy have a negative effect on cells by 
inducing apoptosis.  HSP27 expression is low or absent in hormone naïve prostate cancer, 
with increasing levels demonstrated in tumours once treatment is commenced.  In CRPC,   38
HSP27 is uniformly overexpressed and it is thought that this molecular chaperone is 
important in the progression of prostate cancer from hormone sensitive to resistant (103).  
The development of hormone resistance is thought to be attributed to decreased apoptotic 
rates rather than an increase in proliferation (104).  The antisense oligonucleotide OGX-
427 which targets HSP27 has been shown to inhibit HSP27 expression and synergises with 
androgen ablation and chemotherapy in prostate cancer xenograft models.  In vitro work 
has also been published showing that down regulation of HSP27 radiosensitises prostate 
cancer cells (105).  A phase I clinical trial of the antisense oligonucleotide OGX-427 either 
alone or with docetaxel is currently recruiting patients.    
HSP90 is a key regulator of ligand-independent nuclear localisation and activation 
of AR in androgen-refractory prostate cancer cells (106).  HER2, Raf-1 and Akt are also 
regulated by HSP90.  Geldanamycin and its derivative 17-AAG are anasmycins that 
interfere with the action of HSP90 leading to the degradation of HSP client proteins.  Both 
have been shown to have anti-tumour effects in prostate cancer cells.  Despite its potential 
use as an effective cancer treatment, geldanamycin presents several major drawbacks as a 
candidate drug, particularly with hepatotoxicity.  17-AAG however has a more favourable 
toxicity profile.  Using an in vivo prostate cancer model, 17-AAG inhibited tumour growth 
as well sensitised tumour responses to taxol treatment (107). 
Phase I data has recently been published of 17-AAG in patients with advanced 
cancer of which 18 of the 54 patients had CRPC (108).   No partial or complete responses 
were observed with only 1 CRPC patient demonstrating a 25% decline in PSA with 
treatment.  17-AAG may however be more beneficial in enhancing the effect of cytotoxic 
therapy rather than as a monotherapy.  Phase I and II trials are therefore currently 
recruiting patients for treatment in combination with docetaxal and other cytotoxics. 
 
1.6.7 Anti-angiogenic  agents 
Inhibition of angiogenesis has emerged as a promising therapeutic target for a 
number of solid tumours.  Anti-angiogenic agents can reduce intra-tumoural interstitial 
pressure and increase drug delivery of anti-cancer agents.  This mode of anticancer therapy 
has been successful recently in the treatment of renal cell carcinoma (RCC).  Sorafenib is 
an orally active multikinase inhibitor which seems to have an anti-angiogenic effect in 
RCC due to its inhibitory effect toward vascular endothelial growth
  factor receptors 
(VEGFR) and their targets.  Increased production of VEGF is implicated in the progression   39
of clear-cell
  RCC (109).  Sorafenib has been licensed for maintenance treatment of 
metastatic RCC following the positive result in trial in advanced clear cell RCC (110).   
Over-expression of vascular endothelial growth factor (VEGF) and its receptors are 
associated with the progression of prostate cancer (111).  VEGFR-2 inhibition in 
orthotopic prostate cancer models reduced tumourigenicity and metastases, supporting the 
potential use of anti-VEGF agents in prostate cancer (112).  Results of phase II trials using 
Sorafenib in CRPC however have shown minimal effects on PSA response or radiographic 
appearance of bone metastases (113-115). 
Bevacizumab is a humanised murine mAb to VEGF which has been shown to 
provide clinical benefit in colorectal, NSCLC and breast cancer.  Combining bevacizumab 
with 5-fluorouracil inhibits angiogenesis and tumour growth in mouse prostate cancer 
models (116).  Currently bevacizumab is in Phase II studies for use in high risk cases in 
combination with medical or radiotherapy.  A Phase III trial is also recruiting patients with 
CRPC to assess the effect of bevacizumab with docetaxel.   
Platelet derived growth factor (PDGF) is involved in autocrine stimulation of 
tumour cells, regulation of stromal fibroblasts as well as tumour angiogenesis (117).   
Platelet derived growth factor receptor (PDGF-R) is a receptor tyrosine kinase which has 2 
subunits, α and β.  Upon PDGF binding these subunits either homo- or heterodimerize.  
Immunohistochemistry has shown PDGF-R α and β to be expressed in 88% of primary 
prostate tumours and in 80% of bone marrow metastases (118).  Inhibition of this 
signalling pathway appears to be an attractive target in prostate cancer however an initial 
Phase II trial using the PDGF-R inhibitor SU101 showed minimal effect in CRPC (118).   
Imatinib is an inhibitor of PDGF-R signalling as well as the BCR-ABL tyrosine 
kinase.  A number of phase II studies have been done using imatinib in prostate cancer 
patients who have biochemical relapse following radical (radiotherapy or prostatectomy) 
treatment.  As a single agent imatinib has shown limited biochemical activity with a 
significant incidence of grade 3 and 4 toxicity leading in some cases to early trial closure 
(119-121). There has been suggestion that this PDGF-R inhibitor may have a more 
beneficial role if used in combination with taxane based chemotherapy.  Pre-clinical 
models have demonstrated synergistic effects of imatinib and paclitaxel when used in 
mouse models of prostate cancer bone metastases (122).  Recent published results of a 
phase II trial combining imatinib and docetaxel in CRPC patients with bony metastases 
showed no therapeutic benefit despite confirmation of effective p-PDGFR inhibition (123).  
An osteolytic model of bone metastases was used in the preclinical study as opposed to the   40
osteosclerotic lesions typically seen in human prostate cancer, which may contribute to the 
discrepancy in efficacy seen in preclinical model and clinical trial.  High levels of grade 3 
toxicities were also observed in this phase II trial of imatinib and docetaxel and it has been 
recommended that further studies of this combination should not be pursued.   
Other agents with anti-angiogenic properities which may be of clinical benefit in 
CRPC include thalidomide and its analogues.  Thalidomide has multiple mechanisms of 
action including immunomodulatory effects on the tumour microenvironment (124).   
Prostate cancer progression and metastasis has been suggested to be mediated by stromal-
epithelial interactions, which could be targeted by thalidomide.  Thalidomide is also known 
to have anti-angiogenic properties from results of pre clinical studies (125). Phase I and II 
studies showed promising results when thalidomide was used in CRPC patients as well as 
in studies using combination therapy with docetaxel (126-128).  These results support the 
need for additional studies of thalidomide in CRPC either alone or as combination therapy 
and current studies are focussing in particular on the potential effect of thalidomide on 
bone metastases. 
 
1.6.8  The Endothelin Axis 
The endothelin axis (ET axis), comprises of the three peptides endothelin (ET)-1, -
2, -3 and their receptors ET-A and ET-B. Most of the activities of ET-1 are mediated via 
the ET-A receptor.  ET-1 has important roles in a host of biological functions, including 
cellular proliferation, apoptosis and angiogenesis.   It also stimulates osteoblast 
proliferation, leading to osteoblastic bone metastases which is typical of  prostate cancer 
(129).   
In metastatic CRPC endothelin receptors are over-expressed and higher levels of 
endothelin are associated with progressive disease (130).  Atrasentan is a selective 
endothelin-A (ET-A) receptor antagonist that inhibits or reverses the downstream effects of 
endothelin-1 (ET-1).  Phase I and II studies of atrasentan showed encouraging results when 
used in men with metastatic CRPC (131;132).  A phase III trial comparing atrasentan to 
placebo in patients with metastatic CRPC did not show significant delay in disease 
progression (133).  Bone alkaline phosphatase (BAP) was measured as a biomarker of 
disease progression and increases from baseline to final BAP were significantly lower in 
the patients treated with atrasentan.  This suggests that atrasentan may have targeted 
activity in the bone microenvironment and that using this ET-A receptor antagonist may 
potentially prevent bone metastases formation or slow the onset of skeletal related events   41
in CRPC patients.  A phase III trial studying the possible synergistic effect of atrasentan 
and docetaxel is currently recruiting patients with CRPC who have bone metastases.   
 
1.6.9 Anti-apoptotic  proteins 
Accelerated or dysregulated proliferation is well recognised as a major causative 
factor in tumour development and progression.  In addition to this, defective apoptosis 
(programmed cell death) has been highlighted as a key factor in carcinogenesis.   
Disruption of these anti-apoptotic signals through selective therapeutic targeting could 
offer a novel strategy for drug development programmes and a number of potential targets 
are currently being reviewed.  Survivin is a proto-oncogene which is a member of the 
inhibitor of apoptosis family and has been associated with phenotypically aggressive 
prostate cancer and androgen resistance (134;135).  Inhibition of this pathway would aim 
to lower the anti-apoptotic threshold in cancer cells.  YM155 is a novel small molecule 
inhibitor of survivin which induces apoptosis in prostate cancer cell lines and regression of 
tumour growth in CRPC xenografts (136).  Phase II trials are currently under way with 
YM155 and docetaxel in CRPC.   
It has recently been shown that IGF-1/ mTOR signalling increases levels of 
survivin in prostate cancer cells (137).  This suggests that suppression of IGF-1/Akt/mTOR 
signalling may be beneficial to lower an anti-apoptotic threshold maintained by survivin in 
aggressive prostate cancer. 
Bcl-2 is another anti-apoptotic regulatory protein, which is associated with poor 
therapeutic response and poor clinical outcome in small cell lung cancer (SCLC).  There is 
also strong in vitro evidence to show that bcl-2 suppression in SCLC is associated with 
enhanced chemosensitivity.  Disappointingly, a phase II study in patients with advanced 
SCLC treated with carboplatin and etoposide +/- G3139 (or oblimersan, a bcl-2 antisense 
oligonucleotide) showed no added effects with the addition of oblimersan; there was in fact 
a potential negative impact on survival. (138).  Of note oblimersan combined with 
chemotherapy has been shown to improve survival in melanoma patients (139).  To explain 
the negative results in SCLC, two possible explanations are: (1) Despite promising data 
from in vitro and in vivo model systems, bcl-2 over-expression does not play a critical role 
in clinical SCLC, which would argue for more relevant in vivo model systems.  (2) 
Oblimersan is not suppressing bcl-2 at a sufficient level for it to enhance chemotherapeutic 
sensitivity.  Tumour biopsy following oblimersan treatment would enable formal 
assessment of the target status, an important consideration for future trial design.  Finally,   42
it may also be possible that off-target effects such as immunostimulatory effects may be 
responsible for the effects observed in melanoma but not in SCLC.  
Bcl-2 is over-expressed in CRPC (140), and its inhibition results in delayed 
development of hormone resistance and enhanced effects of chemotherapy in prostate 
cancer mouse models (141).  A Phase II study of docetaxel with oblimersan showed no 
additional benefit in overall survival and PSA response rates to docetaxel monotherapy in 
CRPC (142).  Protein expression of bcl-2 was analysed in peripheral blood mononuclear 
cells pre and post treatment in order to assess the pharmacodynamics of oblimersan 
treatment.  No correlations between bcl-2 levels and response rates or survival were noted.  
However, once again, intra-tumoural biomarker, namely bcl-2 level, was not ascertained.  
Currently there are no trials recruiting prostate cancer patients for treatment with 
oblimersan. 
 
1.6.10  Androgen receptor signalling 
Targeting the reactivation of AR signalling in CRPC is currently the focus of many 
drug development programmes and clinical trials.  Anti-androgens currently approved for 
use in prostate cancer (bicalutamide, flutamide, cyproterone acetate) have limited use in 
hormone resistant disease and all have been observed to convert to agonists in progressive 
disease (143).  A number of novel anti-androgens are currently being introduced which 
have significantly higher affinity than bicalutamide for the AR.  Both novel antiandrogens 
MDV-3100 and BMS-641988 are currently in Phase I clinical trial in CRPC. 
CRPC progression may be due to residual serum androgens as well as upregulated 
intracrine androgen synthesis from the tumour cells.  Therefore methods to further lower 
androgen levels are under investigation.  Ketaconazole is a synthetic anti-fungal agent, 
which is currently used in some centres for patients with CRPC due to its action as a potent 
inhibitor of CYP450-dependent adrenal and testicular androgen production.  Studies have 
shown that ketaconazole has a modest activity in CRPC however its use is associated with 
a rise in adrenal androgen levels at the time of progression (144;145).   
Cytochrome P (CYP) 17 is a microsomal enzyme that catalyses two key steroid 
reactions in both adrenal and tumour intracrine androgen biosynthesis involving 17 alpha-
hydoxylase and C (17,20)-lyase.  Abiraterone acetate is a selective, irreversible inhibitor of 
CYP17, suppressing testosterone to castrate levels in the short term; however there is some 
testosterone recovery with long-term use.  Addition of this CYP17 inhibitor to GnRH 
analogue treatment results in decreases in both testosterone and adrenal androgen levels   43
(146).  Abiraterone has recently been assessed in a phase I study to be safe and may have 
favourable antitumour activity (147).  A phase III study is currently recruiting patients with 
CRPC who have progressive disease despite docetaxel treatment. 
Testosterone is converted to dihydrotestosterone (DHT) in peripheral androgen 
dependent tissues by two isoforms of 5 α-reductase, SRD5A1 and SRD5A2.  The type 2 
enzyme has been identified as the dominant type in benign prostate tissue and finasteride, a 
specific type 2 inhibitor, is approved for use in BPH.  It was previously suggested that 
finasteride may prevent or delay the development of prostate cancer.  The Prostate Cancer 
Prevention Trial studied men who were prescribed either finasteride or placebo for seven 
years (148).  Although a 24.8% reduction in the prevalence of prostate cancer in men on 
finasteride was observed, treatment with this 5 α-reductase inhibitor was associated with a 
significant increase in high grade disease.  Dutasteride (a dual inhibitor of SRD5A1 and 
SRD5A2) is currently being evaluated as a chemopreventive agent in prostate cancer as 
SRD5A1 has been shown to be upregulated in progressive prostate cancer (149).   
Dutasteride has also been shown to inhibit in vivo tumour growth when combined with 
castration in androgen responsive xenograft models (150).  In addition, Phase II and III 
trials are currently recruiting patients with prostate cancer of various stages for assessment 
of treatment with dutasteride alone or in combination with androgen deprivation therapy. 
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1.7  Targeting tumour suppressor genes 
In addition to inhibiting oncogenic signalling, drug development programmes are 
also targeting tumour suppressor genes through either activation or induced expression as 
an alternative approach for advanced prostate cancer therapy. 
 
1.7.1  p53 and prostate cancer  
While the frequency of p53 mutations in early prostate cancer is low, heterozygous 
loss of function mutations are often observed in advanced disease (151).  Furthermore, p53 
turnover is maintained by the E3 ubiquitin ligase murine double minute 2 (MDM2) which 
binds to the c-terminus of p53 and targets it for degradation.  Over-expression of this p53 
regulator has been observed in several cancer types including prostate cancer (152).   
Inhibition of the interaction between MDM2 and p53 allows reactivation of p53, and this is 
currently a promising anti-cancer strategy.  Small molecule MDM2 inhibitors such as 
nutlin-3 have shown promising anti-tumour activity in LNCaP xenograft models (wild type 
p53) (153).  Recent evidence suggests that p53 signalling is also important in androgen 
signalling with wild type p53 over-expression being associated with decreased androgen 
function (154).  In vitro treatment with nutulin-3 has been shown to have a suppressive 
effect on androgen signalling (155).  Antisense MDM2 oligonucleotide (AS-MDM2) is 
another method of targeting the interaction between MDM2 and p53.  Treatment with AS-
MDM2 enhanced the in vitro efficacy of radiotherapy and chemotherapy in prostate cancer 
cells (156).  In vivo AS-MDM2 sensitises androgen sensitive xenografts to androgen 
deprivation therapy (157).  The MAPK and PI3K pathways are also involved in p53 
regulation.  p53 can activate the Raf/MEK/ERK pathway and ERK can stabilise p53 by 
phosphorylation in cervical cancer cells (158).  On the other hand, Akt phosphorylates 
MDM2, enhancing its activity and destabilising p53 (159).  The p53, PI3K and MAPK 
pathways are connected functionally and targeting these signalling systems either in 
isolation or together may further synergise the effects of specific (conventional) therapies 
in prostate cancer.  Therefore, it is important to incorporate relevant robust patient 
selection and accurate target validation in the design of future trials in the assessment of 
novel therapies. 
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1.7.2  Epigenetics in prostate cancer 
Epigenetic changes encompass a number of reversible cellular events including 
DNA methylation and histone modifications, which can modulate gene expression and 
alter tumour phenotypes.  A number of genes are hypermethylated and silenced in prostate 
cancer such as GSTpi, commonly hypermethylated in prostate cancers (>90%) (160).   
DNA methylation levels can be altered by chemical inhibition of DNA MTase enzymes.  
However, to date, no demethylating agent has shown significant response in solid tumours 
(161;162).  
Modification of the surrounding histones in which the DNA is packaged is another 
important epigenetic mechanism involved in carcinogenesis.  The expression of histone 
deacetylases (HDAC) is frequently upregulated in prostate cancer with increased 
expression being associated with hormone refractory disease (163).  HDAC inhibitors 
induce growth arrest and apoptosis in vivo as well as regulate angiogenic and immune 
functions (164).  Limited response however has been observed with HDAC inhibitors in 
solid tumours (165).  Although an increase in histone acetylation was observed in the 
peripheral-blood mononuclear cells of patients treated, the histone acetylation status in the 
target organ was not assayed.  Overall, HDAC inhibition alone does not appear to be 
effective as a cancer therapy (165). 
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1.8  The MAPK signalling pathway 
The mitogen-activated protein kinases (MAPKs) are a family of serine/threonine 
kinases including the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), 
ERK5, c-Jun NH2-terminal protein kinase (JNKs) and p38 MAPKs.  The MAPK signaling 
cascade is involved in various cellular functions including cell proliferation, differentiation 
and migration.  Each subfamily of MAPKs can be stimulated by a separate protein kinase 
cascade that leads to the activation of a specific MAPK kinase kinase (MAPKKK) and a 
MAPK kinase (MAPKK), leading to the phosphorylation and activation of the downstream 
MAPK.  ERK1 and ERK2 are isoforms of the ‘classical’ MAPK, ERK1/2 which is 
activated by MEK1/2 following stimulation by a variety of mitogens and is known to be 
important in cell proliferation. 
 
1.8.1 MEK5/ERK5  signalling  pathway 
Mitogen/extracellular signal regulated kinase kinase-5 (MEK5) is the most recently 
identified MAPKK and has been shown to specifically activate ERK5.   ERK5, also known 
as Big MAP kinase 1 (BMK1) is almost twice the size of other MAPKs (815 amino acids).  
The N-terminal kinase domain of ERK5 is highly homologous to ERK1/2 however its 
large C-terminal domain is unique and is thought to be responsible for its unique biological 
activities.   
Cellular stimulation of ERK5 is induced in response to growth factors, oxidative 
stress, and hyperosmolar conditions. EGF is a potent activator of ERK5 and ERK5 has 
been shown to be required for EGF-induced proliferation and progression through the cell 
cycle(166).  A number of tyrosine kinases are recognised to activate the ERK5 pathway 
including the epidermal growth factor receptor (167), HER2/Neu (168)and Src (169). 
Oncogene products such as Ras (167) and COT (170)can also activate the MEK5/MERK5 
pathway.   
In resting cells, over-expressed ERK5 localises to the cytoplasm.  When co-
expressed with constitutively active MEK5 however ERK5 translocates to the nucleus 
(171).  A proposed mechanism for this nuclear shuttling relies on the nuclear localization 
and export signals (NLS and NES) thought to be located in the C-terminal domain, which 
determine the subcellular localization of ERK5 depending on its phosphorylation status 
(see Figure 1.2) (172).   
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FIGURE 1.2 
 
Mechanism controlling ERK5 nucleocytoplasmic transport 
ERK5 has a nuclear localisation signal (NLS) in its carboxyl-terminal tail.  In 
unstimulated cells, a nucleur export signal (NES) is produced by the interaction between 
the amino- and carboxyl-terminal halves, which results in ERK5 being retained in the 
cytoplasm.  Upon stimulation however this interaction is disrupted, abolishing the NES 
activity and thus ERK5 enters the nucleus. 
Modified from Nishimoto et al 2006 (173) 
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MEK5 phosphorylates and activates ERK5 with activation being shown to be 
accompanied by the phosphorylation of Thr
219 and Tyr
221, with the former residue being 
phosphorylated preferentially (174).  These residues lie in a Thr-Glu-Tyr (TEY) sequence 
on the N-terminus of ERK5 which is equivalent to the Thr-Xaa-Tyr motifs of other MAPK 
members, whose phosphorylation is required for activation.  The activation and 
phosphorylation of these residues results in the phosphorylation of ERK5 downstream 
effectors as well as the phosphorylation of the C-terminal region of ERK5 itself (see Figure 
1.3) (175).  The role of this autophosphorylation is unclear but is thought in turn to lead to 
increased activity of its target molecules (173).  Further studies are required to uncover 
how this C-terminal region may enhance transcriptional activity. 
 
FIGURE 1.3 
 
Proposed mechanism by which ERK5 transmits signals to downstream effectors 
Upon activation by MEK5, ERK5 phosphorylates both downstream targets and the 
carboxyl-terminal of ERK5 itself (autophosphorylation), which in turn leads to increased 
activity of its downstream effectors. 
Modified from Nishimoto et al 2006 (173) 
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1.8.2  Transcriptional activity of ERK5 
Upon translocation to the nucleus, ERK5 can control the transcription of 
downstream effectors to elicit the desired cell response.  Three members of the myocyte 
enhancer factor (MEF) family, are known to be substrates of ERK5; MEF2A, C and D.   
MEF2D is a specific substrate of ERK5, however both p38 MAPKs and ERK5 mediate the 
transcription of MEF2A and MEF2C (176).  MEF2 activation involves a MEF2-interacting 
region and a transcriptional activation domain both of which are found in the C-terminal 
tail of ERK5 (177).  Other direct substrates of ERK5 include c-Fos and Fra-1, c-Myc and 
Sap1a (167;178).  RSK p90 ribosomal S6 protein kinase (rbS6) has been implicated in the 
downstream signalling of ERK5 (179).   RSK is thought to be involved in the regulation of 
nuclear factor kappa B (NFκB) function which has also been shown to be involved in 
ERK5 signalling (180;181). 
 
1.8.3  ERK5 and ERK1/2 
The ERK5 and ERK1/2 pathways have a number of similarities and interaction 
between the pathways has previously been suggested (182).  Initial work using the 
MEK1/2 specific inhibitors PD98059 and U0126 showed that inhibition of the ERK1/2 
pathway produced a sustained activation of the MEK5/ERK5 pathway following EGF 
stimulation in HeLa cells (182).  More recently enhanced nucleur accumulation of ERK5 
in NIH3T3 cells was observed following suppression of ERK1/2 by low dose (1µM) 
PD184352 (an MEK1/2 inhibitor) (183).   There has also been suggestion that ERK5 may 
in fact regulate some of the cellular functions originally attributed to ERK1/2.  A number 
of studies have demonstrated the ability of MEK1/2 inhibitors to block ERK5 activation at 
high dose (167;182). Treatment with low dose PD184352 (0.3µM) sufficient to block 
ERK1/2 activation only has been shown to have no significant effect on proliferation 
whereas treatment with higher dose (3µM) sufficient to block ERK5 significantly inhibited 
proliferation (184). These results suggest that it is in fact ERK5 rather than ERK1/2, which 
has the major role in cell proliferation. 
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1.8.4   ERK5 and cancer 
1.8.4.1   Activation of ERK5 by oncogenes 
Mutant Ras has been identified in many different cancers and the ERK5 signalling 
cascade is thought to be among the pathways involved in mediating its oncogenic effects.   
Raf-1, which is a downstream effector of Ras, has also been shown to enhance ERK5 
activity (185).  In addition to Ras other oncogenes such as COT and Src have been 
identified as potential ERK5 activators(169;170;183). 
 
1.8.4.2   ERK5 tumour associated angiogenesis 
In vivo studies have shown that ERK5 signalling has a critical role in embryonic 
angiogenesis with embryonic lethality occurring at 10.5 days post coitum due to 
cardiovascular defects in ERK5 knockout mice (186) .  Xenograft studies have also shown 
a crucial role of the ERK5 pathway in tumour associated angiogenesis (187).   Deletion of 
the host ERK5 gene significantly inhibited the development of tumour vasculature and 
growth of tumour xenografts.  Studies in endothelial cells suggest that the ERK5 pathway 
is involved in tumour neovascularisation through its role in regulating the RSK-rbS6 
pathway. 
 
1.8.4.3   ERK5 and breast cancer 
  The MEK5/ERK5 signalling pathway has been shown to be important in human 
breast carcinoma.  As discussed in section 1.5.2, HER2 gene amplification and protein 
overexpression is found in 20-30% of invasive breast cancers (28).  It has been shown that 
the ERK5 pathway is constitutively activated in cancer cells overexpressing HER2 and that 
down regulation of this pathway significantly reduces the malignant growth of these cells 
(188).  ERK5 resides in the nucleus of cells that overexpress the HER2 receptor and recent 
work has found that nuclear ERK5 favours MEF-2 dependant transcriptional activity and 
inhibits TRAIL( tumour necrosis factor related apoptosis)-induced cell death (189). 
  Apoptosis is known to be the primary route of cytotoxicity by many forms of anti-
cancer therapy however chemoresistance can often become a therapeutic problem.  In vitro 
studies have highlighted the importance of the MEK5/ERK5 pathway in mediating breast 
cancer cells sensitivity to apoptotic inducing events (190).  Overexpression of MEK5 in 
APO- MCF7 cells suggests that this MAPK member may represent a significant potent 
survival molecule.  Further work will confirm if inhibition of this signalling pathway could 
promote for sensitising breast cancer cells to chemotherapeutic regimens and if successful 
may be of significance in other chemoresistant cancer.  
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1.8.4.4   ERK5 and prostate cancer 
Over recent years, abnormal MEK5/ERK5 signalling pathway has been shown to 
be important in prostate carcinogenesis.  Strong MEK5 expression correlates with 
aggressive disease and activation of MEK5 signalling induced proliferation, motility and 
invasion in LNCaP prostate cancer cells (191).  
More recently, abnormal ERK5 function has also been suggested to contribute to 
prostate carcinogenesis (184).  ERK5 immunoreactivity is significantly up-regulated in 
prostate cancer when compared to benign prostatic hyperplasia. Increased levels of ERK5 
cytoplasmic signals correlated closely with Gleason sum score (p<0.0001), bone 
metastases (p=0.0044) and locally advanced disease at diagnosis (p=0.0023), with a weak 
association with shorter disease-specific survival. A subgroup of 15 (of 81) patients 
showed strong nuclear ERK5 localisation, which correlated with poor disease-specific 
survival and, on multi-variant analysis, was an independent prognostic factor (p<0.0001).  
In addition PC3 cells over-expressing ERK5 displayed enhanced proliferation, migration 
and invasion.  Taken together, these data suggest MEK5/ERK5 pathway to be biological 
important in prostate cancer and a potential target in invasive prostate cancer. 
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1.9  Aims and Objectives of the Study 
 
The specific aims of this study are: 
•  To study ERK5 expression in resected prostate cancer specimens including primary 
tumours and metastatic lesions 
 
•  To investigate the functional and biochemical effects  of ERK5 inhibition in 
prostate cancer cells  
 
•  To explore potential cross talk between ERK1/2 and ERK5 signalling pathways 
 
•  To optimise methodology to study the ERK5 interacting proteome 
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2  Materials & Methods 
2.1 Materials 
Immunohistochemistry 
•  Normal rabbit serum          Vector Labs, Peterborough, UK 
•  Vectastain         Vector  Labs,  Peterborough,  UK 
•  DAB substrate kit          Vector Labs, Peterborough, UK 
•  EnVision plus reagents       DAKO,  Cambridgeshire,  UK 
 
Cell Lines 
•  PC3  cells       ECACC,  Salisibury,  UK 
•  PC3  ERK5       Newcastle  University,  UK  (184)   
•  PC3  Empty  vector      Newcastle  University,  UK  (184) 
•  HEK  293       BICR,  Glasgow,  UK     
 
Tissue Culture 
•  RPMI  1640       Invitrogen,  Paisley,  UK 
•  DMEM      Invitrogen,  Paisley,  UK   
•  Fetal  Bovine  Serum      Invitrogen,  Paisley,  UK 
•  G418          Invitrogen,  Paisley,  UK   
•  L-glutamine       Invitrogen,  Paisley,  UK 
•  Recombinant human EGF        R&D systems, Abingdon, UK 
•  PD184352       Strathclyde  University,  UK 
 
Western analysis 
Protein extraction 
•  Calbiochem cocktail mixture       Calbiochem, Nottingham, UK 
•  Bio-rad Protein Assay         Bio-rad Labs, Herts, UK 
SDS-PAGE 
•  Pageruler prestained protein ladder      Fermentas Life Sciences, York, UK 
•  NuPAGE 10% Bis-Tris Gel     Invitrogen,  Paisley,  UK 
•  MOPS  Running  Buffer     Invitrogen,  Paisley,  UK 
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Blotting and detection 
•  ECL Western Blotting Detection Kit   Amersham,  Buckinghamshire,  UK 
•  Immobilon-P       Millipore,  Herts,  UK 
•  Super  RX  medical  x-ray  film     Fujifilm,  Bedfordshire,  UK 
 
Antibodies        
Antibody against  Company 
ERK5, rabbit polyclonal  Cell Signalling, Herts, UK 
ERK5, rabbit polyclonal  Upstate, Herts, UK 
phospho ERK5, rabbit polyclonal  Cell Signalling, Herts, UK 
ERK 1/2, rabbit polyclonal  Cell Signalling, Herts, UK 
phospho ERK 1/2, rabbit polyclonal  Cell Signalling, Herts, UK 
α tubulin, mouse monoclonal  Santa Cruz, Heidelberg, Germany 
actin, mouse monoclonal  Sigma-Aldrich, Dorset, UK 
GFP, mouse monoclonal  Living colours, Saint-Germain-en-Laye, France 
PCNA, mouse monoclonal  Cell Signalling, Herts, UK 
MEK1/2, rabbit polyclonal  Cell Signalling, Herts, UK 
NFκB p65, mouse monoclonal  Santa Cruz, Heidelberg, Germany 
phospho NFκB p65, rabbit polyclonal  Cell Signalling, Herts, UK 
HRP-conjugated anti-mouse IgG  Cell Signalling, Herts, UK 
HRP-conjugated anti-rabbit IgG  Cell Signalling, Herts, UK 
Biotinylated anti sheep IgG  Vector Labs, Peterborough, UK 
     
 
Transient transfection  
•  HiPerfect Transfection Reagent      Qiagen, Crawley, UK 
•  siRNA suspension buffer        Qiagen, Crawley, UK 
•  ERK5 siRNA (custom made)      Eurogentec,  Seraing,  Belgium 
•  ERK1  siRNA       Dharmacon,  Chicago,  USA 
(MAPK 3 on-TARGET plus  SMARTpool)  
•  ERK2  siRNA       Dharmacon,  Chicago,  USA 
(MAPK 1 on-TARGET plus SMARTpool)  
•  All stars negative control siRNA      Qiagen,  Crawley,  UK 
•  Cell line nucleofector Kit V         Amaxa, Cologne, Germany 
•  Cell line nucleofector Kit L        Amaxa, Cologne, Germany   55
•  Lipofectamine  2000      Invitrogen,  Paisley,  UK 
•  pCMV FLAG tag ERK5        Newcastle University, UK (184) 
•  pCMV  FLAG  tag  EV      Newcastle  University,  UK(184) 
•  FLAG  peptide       Sigma-Aldrich,  Dorset,  UK 
 
Invasion assays 
•  Biocoat Matrigel Invasion Chamber      Becton Dickinson, Oxford, UK 
 
Immunoprecipatation 
•  Leupeptin       Cambridge  Bioscience,  UK 
•  Aprotinin,  bovine  lung    Sigma-Aldrich,  Dorset,  UK 
•  Protein A Sepharose beads      Sigma-Aldrich,  Dorset,  UK 
•  Protein G Sepharose beads      Sigma-Aldrich,  Dorset,  UK 
•  DMP        Pierce,  Rockford,  USA   
•  SimplyBlue SafeStain       Invitrogen,  Paisley,  UK 
•  Micro Bio-Spin Chromatography Columns     Bio-rad Labs, Herts, UK 
•  NuPAGE SDS Running Buffer    Invitrogen,  Paisley,  UK 
•  4x NuPAGE LDS Sample Buffer     Invitrogen,  Paisley,  UK 
•  10x NuPAGE sample reducing agent     Invitrogen, Paisley, UK 
•  Biomax  5K  membrane    Millipore,  Herts,  UK 
•  Anti-FLAG M2-Agarose from mouse  Sigma-Aldrich,  Dorset,  UK 
 
 
SILAC 
•  RPMI Media for SILAC        Pierce, Rockford, USA 
•  DMEM Media for SILAC        Pierce, Rockford, USA 
•  Dialyzed  FBS       Pierce,  Rockford,  USA   
•  13C6  L-Lysine-2HCl      Pierce,  Rockford,  USA 
•  L-Lysine-2HCl     Pierce,  Rockford,  USA 
•  L-Arginine-HCl      Pierce, Rockford, USA 
•  13C6  15N4  L-Arginine     Pierce,  Rockford,  USA 
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2.2 Immunohistochemistry   
2.2.1 Preparation  of  agar cell pellets 
In order to optimise antibody concentrations for immunohistochemistry 
experiments agarose cell pellets were made with PC3-ERK5 (PC3 cells stably 
overexpressing ERK5) and PC3 EV (empty vector) cells (both obtained from Newcastle 
University (184)).  2 x10
7 cells were used per pellet and following trypsinisation, cells 
were washed twice in PBS before being resuspended in 1 ml neutral buffered formalin and 
being left at room temperature for 1-2 hours.  Following a final spin (5 minutes, 1000rpm) 
cells were resuspended in 1ml 2.5% agarose which had previously been warmed to 50
oC.  
These samples were then wax embedded and sections cut (4µm) for immunostaining 
experiments. 
 
2.2.2 ERK5  immunostaining 
Archive paraffin wax-embedded sections (4µm) were used from clinical prostate 
and kidney samples. Xenograft tumours were obtained from Newcastle University (184).  
Mouse heart sections were used as a positive control and no primary antibody was used as 
a negative control.  All sections had previously been baked overnight at 50
oC.  Sections 
were deparaffinised in histoclear and rehydrated through graded alcohols before a final 
wash in water.  Endogenous peroxidase activity was blocked by incubating samples in 
0.3% hydrogen peroxide for 15 minutes.  Antigen retrieval was achieved by immersion in 
pre-heated 0.01M pH6 sodium citrate buffer and microwaving for 4.5 minutes at full 
power in a pressure cooker.  Slides were placed into distilled water immediately following 
this.  Sections were then incubated with 150µl of rabbit serum (Vector Labs, Peterborough, 
UK) in 10ml of 0.1% fraction V BSA in 0.15M NaCl PBS for 1 hour before incubation 
with the desired primary antibody overnight at 4
oC.  After washing in 0.1% BSA/PBS 
slides were incubated with the secondary antibody (Biotinylated anti sheep IgG, Vector, 
Labs, Peterborough, UK) diluted 1:200 in BSA/PBS for 1 hour at room temperature.   
Slides were then washed again with BSA/PBS before incubation with Vectastain (Vector 
Labs, Peterborough, UK) for 1 hour.  Following a final wash with BSA/PBS, 
diaminobenzidine tetrahydrochoride (DAB substrate kit, Vector Labs, Peterborough, UK) 
was applied to the slides for 5 minutes.  The slides were then washed in distilled water 
before counterstaining with haematoxylin. 
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2.3  Cells and Cell culture 
PC3, PC3M and DU145 cells were maintained in RPMI 1640 (Invitrogen, Paisley, 
UK) and HEK 293 cells in DMEM growth medium (Invitrogen, Paisley, UK).  All medium 
was supplemented with 10% heat-inactivated FBS (Invitrogen, Paisley, UK) and 1% L-
Glutamine (Invitrogen Paisley, UK).  The transfected cell lines PC3 ERK5 and PC3 EV 
were generated as previously described (192), and maintained as the parental cells with the 
culture medium supplemented with 300ug/ml geneticin (G418)(Invitrogen, Paisley, UK).  
All cells were incubated at 37
oC and 5% CO2. 
 
2.4  Western blot analysis 
2.4.1 Protein  extraction 
Cultured cells were lysed in buffer (50mM Tris pH 7.6, 150mM NaCl, 1% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1mM Na3VO4, 1mM NaF, calbiochem 
protease inhibitor cocktail x1, 0.1µg/ml okadaic acid). 
 
2.4.2  Determination of protein concentration 
The protein concentration of the whole cell and nuclear extracts was determined 
using a colourimetric assay based on the Bradford dye-binding method (193).  5µl of lysate 
was mixed in a cuvette with 1ml of a 4:1 solution of H2O: Bio-rad Protein Assay (Bio-rad 
Laboratories, Herts, UK).  The protein concentration was measured using an Eppendorf 
BioPhotometer (Eppendorf UK Ltd, Cambridge, UK) and the standard curve was drawn 
from six BSA standards at 80, 100, 200, 400, 1000 and 2000µgml
-1 in the same buffer as 
the protein samples being measured. 
 
2.4.3  Polyacrylamide gel electrophoresis of proteins 
Proteins were resolved by polyacrylamide gel electrophoresis through a pre cast 
10% Bis-Tris polyacrylamide gel (Invitrogen, Paisley, UK), electrophoresed in MOPS 
running buffer (Invitrogen, Paisley, UK) for 1 hour at 200V.  20µg of protein extract in a 
volume adjusted to 20µl with dH2O was combined with 10µl of 3x sample loading buffer 
(0.187M Tris H-Cl pH 6.8, 6.9% SDS,  0.003 % bromophenol blue, 30 %glycerol, 15% 
mercaptoethanol) and 25µl loaded per lane. 
 
2.4.4  Blotting and hybridisation to antibody 
After separation by polyacrylamide gel electrophoresis, proteins were then 
transferred to Immobilon-P (Millipore, Herts, UK) by semi-dry blotting buffer (3.03g/l Tris 
base, 14.4g/l glycine, 0.1g/l SDS, 20% methanol).   Blots were incubated in blocking   58
solution (TBST containing 5% Marvel) for 30minutes before being incubated in the 
primary antibody diluted at the appropriate concentration in 5% BSA in TBST.  Blots were 
washed five times in TBST and then incubated in 5% Marvel containing anti-rabbit, anti-
mouse or anti-sheep immunoglobulin horseradish peroxidase-linked whole antibody, 
diluted as directed by the manufacturer (Cell Signalling, Herts, UK).  All incubations with 
secondary antibody were for 1 hour at room temperature with gentle agitation.  Blots were 
then washed a further five times in TBST.  Proteins were visualised using ECL western 
blotting chemiluminescent detection reagent (Amersham, Buckinghamshire, UK) followed 
by autoradiography, where the membrane was wrapped in Saranwrap, placed in a medical 
x-ray cassette, and overlayed with xray film.  Exposure was initially for 30seconds to 
determine optimal exposure times.  The autoradiograph was developed using a Kodak X-
OMAT 3000RA x-ray processor. 
 
 
2.5 siRNA  transfection 
2.5.1 Transfection  test 
In order to optimise technique an initial transfection test was performed using a 
fluorescent labelled siRNA, Alexa Fluor 488, and HiPerfect (all Qiagen, Crawley, UK) as 
the transfection reagant.  Two 12 well plates were seeded with 0.6x10
5 PC3 cells the day 
before and the day of transfection.  Different ratios of Alexa Fluor 488, serum free medium 
and HiPerfect were used to establish the most efficient transfection in PC3 cells.   After 24 
hours the medium was changed and the cells were observed at 48 hours using a confocal 
microscope.  
 
2.5.2 HiPerfect  transfection 
The duplex oligonucleotide 5’-GGTGTTGGCTTTGACCTGGAGGAAT-3’ was 
ordered from Eurogentec, (Seraing, Belgium) (preannealed).  All experiments were 
performed using a final concentration of 10nM ERK5 siRNA.  PC3 and PC3 ERK5 cells 
were used for ERK5 siRNA transfection with HiPerfect as the transfection reagent.  All 
stars negative control siRNA (AS-ve, sequence not provided) was used in parallel to 
control for non-specific effects.  Monitoring of gene silencing was done by Western 
blotting and siRNA transfected cells were used for proliferation, migration and invasion 
assays. 
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2.5.3  Amaxa transfection  
siRNA transfection was also carried out using an Amaxa nucleofector kit (Amaxa, 
Cologne, Germany).  Kit V, programme T13 was used for PC3 cells.  1x10
6 cells were 
used per transfection in 100µl of nucleofector solution (provided by Amaxa).  Once 
combined with the appropriate siRNA, cells were transferred to an amaxa certified cuvette 
and transfection carried out using a Nucleofector II device (Amaxa, Cologne, Germany).  
Cells were then resuspended in 500µl of medium and 250µl of this transferred to a 6cm 
dish already containing 3.7mls full medium.  Initial experiments were performed to 
identify optimal concentrations of ERK1 and ERK2 siRNA (both Dharmacon, Chicago, 
USA) in PC3 cells.  10nM ERK1 and 100nM ERK2 siRNA was then used for subsequent 
experiments. 
 
2.6 Proliferation  assay 
1.5x10
5 cells were seeded in 6 well plates.  siRNA transfection was performed and 
serial cell counts were taken at 24, 48, 72 and 96 hours using a Casey cell counter. Each 
experiment was repeated three times and 3 wells were used per condition each time.   
 
2.7       Migration assays 
Motility assays were performed 48 hours post transfection with ERK5 siRNA.  Cells 
were plated on glass 6 well dishes for optimal visualisation.  PC3 ERK5 cells were studied 
using a Nikon TE2000 time lapse microscope (x20 magnification).  Images were taken 
every 15 minutes over an 18 hour period.  Image J software was used to track motility and 
accumulated and euclidean (direct) distance were measured.  Cell velocity and persistance 
(euclidean distance/accumulated distance) were also calculated.  Persistence is an indicator 
of the randomness in the cells migration.  The closer to one, the more directly the cell 
moved from start to finish.    Eight cells were tracked per field and 3 fields were viewed in 
each experiment (x2).  
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2.8        Invasion assays 
For invasion assays Biocoat Matrigel invasion chambers (Becton Dickinson, Oxford, 
UK) were used.  The matrigel inserts were rehydrated with serum free medium for 2 hours 
before being transferred to a 24 well companion plate which already has 600µl full 
medium per well.  Overnight serum starved PC3 ERK5 cells were trypsinized and washed 
twice with serum free medium containing 0.5% BSA.  An initial experiment was 
performed to assess optimal seeding density comparing 5x10
4, 7.5x10
4, 1x10
5 per chamber.  
The cells were left to attach and invade overnight at 37
oC and under 5% CO2/ 95% air 
atmosphere.  Cells were seeded in 300ul of serum free medium per insert and after 22 
hours the medium was aspirated and the cells on the upper surface of the membrane were 
removed using a cotton bud.  The invaded cells were fixed in methanol and left at -20
oC 
for 30 minutes prior to staining with haematoxylin.  The chambers were left to air dry 
before the membrane was cut out and mounted on a microscope slide with histomount.  
The migrated cells were then counted using a light microscope at 10x magnification. 
Each experiment was repeated 3 times and each time the mean number of invading cells 
was taken from 4 chambers. 
 
2.9 EGF  stimulation 
Cells were serum starved for 24 hours before stimulated with 50ng/ml EGF (R&D 
systems, Abingdon, UK).  Cells were lysed at various time points (15, 30, 60, 90 and 120 
minutes).   
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2.10 Immunoprecipation 
 
Hepes Lysis Buffer 
20mM Hepes-NaOH pH 7.5  1mM Na3VO4 
150Mm NaCl  5ug/ml leupeptin 
1% NP-40  2.2ug/ml aprotinin 
2mM EDTA  1mM Na3P2O7 
1mM PMSF  20mM β-glycerophosphate 
2mM NaF   
 
Hepes Wash Buffer 
20mM Hepes-NaOH pH 7.5  1mM Na3VO4 
50mM NaCl  5ug/ml leupeptin 
1% NP-40  2.2ug/ml aprotinin 
2mM EDTA  20mM β-glycerophosphate 
1mM PMSF   
2mM NaF   
 
Hepes Cross-linking Wash Buffer 
100mM Hepes-NaOH pH 8.5 
 
 
Hepes Cross-linking Buffer 
100mM Hepes-NaOH pH 8.5 
10mg/ml Dimethyl pimelilidate (DMP) 
 
Glycine Elution Buffer 
200 mM glycine-HCl pH 2.5 
500mM NaCl 
0.01% NP-40 
 
 
 
 
   62
2.10.1  Dimethyl pimelilidate (DMP) cross-linking of antibodies to Protein A / G beads 
100ul of beads were pipetted into a 1.5ml microfuge tube and washed 3 times in 
1ml Hepes lysis buffer by sequentially mixing the beads with the buffer and then 
centrifuging the beads to the bottom of the tube.  100µl of ERK5 antibody or 10µl of pre-
immunised rabbit serum were then added to the beads.  800µl of Hepes lysis buffer was 
also added and these were then incubated at 4
oC overnight.  The next day the beads were 
washed 3 times with 1ml Hepes lysis buffer before washed twice with 1ml Hepes cross-
linking wash buffer.  The beads were then incubated at room temperature with 1ml cross-
linking buffer for 1 hour.  Following this the beads were further washed twice in 1ml 
Hepes cross-linking wash buffer.  The reaction was then quenched by adding 1 ml 100mM 
Tris-HCl pH 7.5 to the beads and mixing at room temperature for 30 minutes.  The beads 
were washed twice with 1ml lysis buffer followed by 2 washes with 1ml elution buffer.  
Following this the beads were washed twice with 1ml Hepes lysis buffer.  200ul lysis 
buffer with sodium azide (0.02%) was added to the slurry.  The cross linked beads were 
then stored at 4
oC. 
 
2.10.2  Preparation of lysate for immunoprecipatation from PC3 cells 
PC3 cells were grown to 70% confluence on 14cm plates.  The plates were then 
washed once with ice cold PBS and lysed with 500ul Hepes lysis buffer.  The lysate was 
then incubated on ice with occasional vortexing.  The lysates were cleared by 
centrifugation at 132000rpm in a cooled (4
oC) bench top centrifuge for 10 minutes.  The 
lysate was incubated with the cross-linked antibody beads overnight.  The following day 
the beads were transferred to a spin column and washed 3 times with ice-cold Hepes wash 
buffer.  Each time the beads were mixed with the buffer prior to removing the buffer by 
centrifugation into a 2ml microfuge tube at 1000rpm.  The lysate which was collected 
following the first spin was collected and labelled as supernatant (SN).  After the last wash 
the dry beads were incubated on ice with two bead volumes of the glycine elution buffer 
for 5 minutes with occasional vortexing.  The eluate was removed by centrifuging 
(6000rpm) into a clean microfuge tube.  This step was repeated once.  The combined 
eluates was neutralised by adding 1/10
th of the eluate volume of 2M Tris-HCl pH 9.  The 
total volume of the eluate was then measured and 20µl was aliquoted and kept at -20
oC to 
use for western blotting.  To concentrate the eluate a 5kDa cut off membrane was used 
(Micro Bio-Spin Chromatography Columns, Bio-rad Labs, Herts, UK).  The eluate was 
transferred to this and then centrifuged at 12
oC, due to the temperature sensitive nature of 
the filter at 16000rpm for 45 minutes.     63
The concentrated sample was then added to LDS sample buffer and reducing agent.  
The sample was denatured by heating to 57
oC for 15 minutes before electrophoresed on a 
10% NuPAGE gel.  The samples were run at constant 100V until the dye front reached the 
end of the gel.  The gel was transferred into a 14cm cell culture dish with a lid and washed 
in 25ml fixing solution (50% ethanol, 10% acetic acid and 40% H2O) for 15 minutes at 
room temperature.  Following this the gel was washed in H2O for 5 minutes, followed by 
an overnight incubation in Simply Blue coomassie stain (Invitrogen, Paisley, UK).  The gel 
was then destained in 25% methanol for 1 minute before being washed several times in 
H2O until the background was clear.  The subsequent mass spectrometry analysis was 
carried out by Dr Willy Bienvenut (Proteomics service, Beatson Institute for Cancer 
Research, Glasgow). 
For each experiment a small amount of eluate was kept pre and post concentration 
and a western blot run to ensure no sample was lost during the concentration step.  A 
sample of the supernatant was also run on the gel to confirm adequate ERK5 pulldown. 
 
2.10.3  Titration of antibody to bead 
In order to optimise the bead to lysate ratio an initial titration experiment was 
performed using the 2 commercially available ERK5 antibodies (Cell Signalling and 
Upstate) and the phospho ERK5 antibody with both Protein A and G sepharose beads (both 
Sigma-Aldrich, Dorset, UK).  A constant ratio of 100µl of antibody crosslinked to 100µl of 
beads was used for the titration experiments.  For each experiment a constant amount of 
lysate was used (100µg) and immunoprecipatation performed as described above.   All 
eluated samples with their corresponding supernatant were then analysed by western 
blotting.  
 
2.10.4 Pre  clearing 
Pre-clearing was performed to reduce non-specific binding of proteins to the beads.  
50µl of normal rabbit serum was added to 1ml of lysate.  This was vortexed and incubated 
on ice for 1 hour.  100µl of protein A sepharose beads were then added to this and 
incubated at 4
oC for 30 minutes with gentle agitation.  Prior to adding the beads to the 
lysate/serum mixture 3 washes with hepes lysis buffer was performed.   This was then 
centrifuged at 132000rpm at 4
oC for 10 minutes.  The bead pellet was discarded and the 
supernatant kept for immunoprecipatation.   
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2.10.5  EGF stimulation for immunoprecipatation 
PC3 cells were grown until 70% confluent in 14cm dishes and then serum starved 
for 24 hours following 2 washes with PBS.  Cells were treated with 50ng/ml EGF before 
the cells were harvested for analysis.  Control cells were lysed after 24 hours and 
immunoprecipatation performed with ERK5 crosslinked beads.   
 
2.10.6  Exogenous ERK5 transfection 
PC3 and HEK293 cells were grown in a 14cm plate until 60% confluent and then 
transfected with 3µg of the plasmid pCMV FLAG ERK5 using Lipofectamine 2000 as a 
transfection reagent.  The plasmid pCMV FLAG EV was used a control.  Cells were lysed 
48hours post transfection and successful transfection validated by western blotting. 
 
2.10.7  FLAG tag immunoprecipatation 
HEK293 cells were used for all FLAG tag immunoprecipatation experiments.  An 
initial experiment was performed with cells grown in full medium on 14cm plates (x10) to 
confirm pull down of ERK5 by mass spectrometry.  Cells were transfected with the 
pCMV5 FLAG ERK5 plasmid and lysed with 1ml per plate HEPES lysis buffer after 48 
hours.  After clearing, the lysate was incubated with 200µl of FLAG beads for 1 hour at 
4
oC.   
The beads were then transferred to a spin column and washed 3 times with ice-cold 
Hepes wash buffer as described previously. After the last wash the dry beads were 
incubated on ice with 200µl of FLAG peptide (Sigma-Aldrich, Dorset, UK) for 10 minutes 
with occasional vortexing.  The eluate was removed as before and this step was repeated 
before concentrating the sample to run on the gel. 
As before a western was run with a sample of the lysate, supernatant and eluate pre 
and post concentration to confirm pulldown of ERK5. 
 
2.10.8  Stable isotope labelling with amino acids in cell culture (SILAC) 
Heavy (
13C6 L-Lysine-2HCl and 
13C6
15N4 L-Arginine-HCl) and light (L-Lysine -
2HCl and L-Arginine-HCl) DMEM media was made up per manufacturers instructions and 
supplemented with 10% dialysed FBS (all Pierce, Rockford, USA).  This was then filtered 
using a 0.2µm filter before being used for cell culture.   
HEK293 cells were grown in each media for a minimum of 5 cell doublings (~7-10 
days) before isotope incorporation efficiency was determined.   
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2.10.9  Determination of Isotope Incorporation Efficiency 
1x10
6 cells of both heavy and light isotope incorporated cells were plated 
separately on 9cm dishes and lysed the following day with 500µl reducing sample buffer.  
The samples were boiled for 5 minutes and clarified by centrifuging at 14000rpm for 1 
minute.  25µl of the heavy and light samples were then loaded into two separate wells of a 
10% pre-cast polyacrylamide gel and the proteins separated by electrophoresis.  The gel 
was fixed and stained as described previously and incorporation efficiency verified by our 
proteomics department using mass spectrometry. 
 
2.10.10 EGF stimulation in HEK 293 cells 
An initial experiment using the HEK 293 cells confirmed poor adherence following 
a PBS wash and therefore serum starvation prior to EGF simulation would not be possible.  
In order to promote cell adhesion 0.1% poly-L-lysine was used to coat the plates the day 
before cells were plated.  36 hours post transfection cells were serum starved overnight 
before being stimulated with 50ng/ml EGF.  Cells were lysed at various time points (15, 
30, 60 and 90 minutes).   
 
2.10.11   Identification of ERK5 associating proteins 
HEK 293 cells grown in the corresponding SILAC media were transfected with 
either pCMV FLAG ERK5 (Experiment 1 – heavy medium, Experiment 2 – light medium) 
or pCMV FLAG EV (Experiment 2 – light medium, Experiment 2 – heavy medium) 
plasmid and lysed after 48 hours.  Prior to incubating the lysate with the FLAG beads, the 
protein concentration of each lysate was measured.  Equal protein amounts of each cell 
lysate were mixed in a 15ml falcon before adding the beads as described previously.  The 
sample was run on a 10% gel and given to the proteomic department for analysis once 
stained.   
 
2.10.12    Identification of ERK5 binding partners 
Prior to plating the cells, 14cm plates were coated with 0.1% poly-l lysine.  SILAC 
treated HEK293 cells were plated and grown until 60% confluent before cells were 
transfected with pCMV FLAG ERK5 and grown for a further 36 hours in full SILAC 
mediums.  Cells were then serum starved overnight before EGF stimulation.  Cells were 
treated with 50ng/ml EGF and lysed at 2 timepoints: time = 0 minutes (Experiment 1 – 
light medium, Experiment 2 – heavy medium) and time = 15 minutes (Experiment 1 – 
heavy medium, Experiment 2 – light medium).  The lysates were treated as above and the 
stained gel given for mass spectrometry analysis.   66
2.10.13  Analysis of data from mass spectrometry study 
The Scaffold 2 proteome software (Proteome Software Inc., Oregon, USA) was 
used to analyse mass spectrometry results.  This programme is the industry-standard 
MS/MS meta-analysis tool and allows comparison of various factors between samples e.g. 
number of peptide matches, percentage coverage and protein identification probability.   
The dataset was separated into four separate categories for analysis; 1-non-relevant hits 
(mostly due to low peptide number or large standard deviation value), 2- potential positive 
hits (medium number of non-redundant peptides and/or medium ratio and/or low 
reciprocity between two samples) 3 - clear positive hits (large number of non-redundant 
peptides with high ratio and high reciprocity between two samples), 4 - remaining proteins. 
 
2.11 Statistical  analysis 
Statistical analysis was performed using SPSS version 15.  Student’s t-test was 
used to compare to compare data that followed the normal (Gaussian) distribution.  A 
statistical significant difference was defined to be a p-value < 0.05.  Where error bars are 
represented on a graph they signify the standard error (SE) of the mean value plotted.  
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3  Target validation – in prostate cancer 
3.1 Introduction 
Molecular targets which are identified as being potentially involved in the 
development of cancer must be validated prior to the initiation of drug development 
programmes.  The target of interest must be shown to be critical in the disease process as 
well as being a valuable point of intervention.  Various methods of target validation are 
used including downregulation of gene expression, protein inhibition and cellular assays.  
Other molecular tools which are commonly used to prioritise targets of interest include 
analysis of proteomic and microarray data. 
 
3.1.1  MEK5/ERK5 signalling in prostate cancer 
Aberrant MEK5/ERK5 signalling is recognised to play an important role in prostate 
carcinogenesis.  Strong MEK5 expression correlates with the presence of bone metastases, 
the most common site of distant metastasis in prostate cancer (191).  In vitro work has also 
shown that MEK5 expression increases matrix metalloproteinase (MMP) 9 expression, an 
enzyme that is implicated in enhancing the metastatic potential of prostate cancer.  In 
addition, immunohistochemistry experiments on human prostate tumours identified 
increased ERK5 cytoplasmic expression to correlate with the presence of bone metastases 
(P=0.0044) (184).  Analysis of ERK5 staining in matched tumour samples (pre and post 
hormone relapse) showed ERK5 nuclear expression to be associated with hormone 
resistant disease (P=0.0078).  ERK5 expression is also upregulated in an androgen 
independent LNCaP subline when compared with the androgen dependent parental cell 
line.    
In order to investigate the role of ERK5 in advanced prostate cancer a tissue 
microarray (TMA) containing both primary and metastatic prostate cancer specimens was 
examined.  The biological effect of suppressing ERK5 expression in prostate cancer was 
also investigated using small interfering RNA (siRNA) in PC3 cells in a number of 
functional assays.  
 
3.1.2 NFκB and ERK5 
There is accumulating evidence implicating the transcription factor Nuclear Factor 
kappa B (NFκB) in carcinogenesis (194).  NFκB is a transcription factor of the Rel protein 
family, which include the p50, p52, p65 (RelA), c-Rel and RelB proteins, and its most 
widely studied form is the p50/p65 heterodimer (195;196).  NFκB is sequestered in the 
cytoplasm bound in an inactive complex with inhibitory IκB proteins, including IκBα and   68
IκBβ (196)[6]. A wide variety of agents activate NFκB, including tumour necrosis factor-α 
(TNF-α), interleukin-1 (IL-1) and lipopolysaccharide (LPS) (195). Most employ the 
canonical pathway of I kappa Kinase (IκΚ) activation, which induces phosphorylation and 
degradation of IκB (see Figure 3.1). This exposes a nuclear translocation signal on the p65 
subunit and permits NFκB transport into the nucleus. There, NFκB controls the 
transcription of numerous genes vital for cell immunity and inflammation, e.g. TNF-α, 
IFNγ, IL-1 and IL-8 (194). Fundamental for tumorigenesis, NFκB also regulates genes 
encoding growth factors (IL-2, IL-6), cell adhesion molecules (intercellular adhesion 
molecule-1, vascular cell adhesion molecule-1), angiogenic factors (VEGF) and 
antiapoptotic factors, (bcl-2 and survivin) (197;198). It also relates with numerous 
components of the cell cycle, including c-myc, cyclins and p53, and acts on the G1/S 
transition (195;199) .  
NFκB is has been shown to be constitutively activated in human prostate cancer, 
and this overexpression, especially of p65, correlates with increased cell invasion and 
tumour stage (200-202). NFκB blockade in PC3M cells decreased invasion, by 
downregulating MMP 9 and collagenase activity, and angiogenesis, through inhibiting 
VEGF and IL-8 expression (203).  Inhibition of NFκB signalling in vivo has also shown 
reduced tumour growth and metastatic potential (203).  
The NFκB pathway has recently been implicated as a downstream target for ERK5 
signalling.  ERK5 is believed not to directly bind to NFκB, but activate it through a non-
canonical pathway (see Figure 3.1).  An intermediate kinase suggested may mitogen-
activated p90 ribosomal S6 protein kinase (RSK) 2, which phosphorylates IκB, targeting it 
for degradation (204;205). This role of RSK2 has been confirmed recently, however it is 
thought that another unidentified kinase is also required for the activation of NFκB by 
ERK5 (206).  ERK5 has been shown to be essential for G2/M progression with NFκB 
being involved at this checkpoint (206).  In fibroblast cells, overactivity of MEK5 and 
MEK1, upstream activators of ERK5 and ERK2 respectively, demonstrated a synergistic 
approach in activating an NFκB-sensitive reporter (207). ERK5 predominantly targets the 
NFκB p65 component, and has been shown to be essential for NFκB-induced survival in 
leukaemic T cells (208).  
Given the fact that NFκB has itself been reported to play an important role in 
prostate cancer, particularly in hormone resistant disease, we aimed to investigate if ERK5 
mediated signalling in prostate cancer cells involves the NFκB pathway. 
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FIGURE 3.1   
 
Normal and alternative pathway for NFκB activation 
Most agents which activate NFκB do so via the canonical pathway of IκK activation which 
induces phosphorylation and degradation of IκB.  Activation by ERK5 however is thought 
to be via an intermediate kinase (RSK2) which phosphorylates IκB, targeting it for 
degradation.  Activated NFκB can then translocate to the cell nucleus and act as a 
transcription factor.  
Modified from Cude et al 2007 (206) 
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3.2 Results 
3.2.1 Antibody  optimisation 
Initial experiments were performed using PC3 ERK5 (PC3 cells overexpressing 
ERK5) and PC3 EV (PC3 cells transfected with the corresponding empty vector) cells to 
confirm the specificity of the ERK5 antibody used.  This confirmed strong ERK5 
immunoreactivity in the PC3 ERK5 cells with weaker immunostaining observed in the 
PC3 EV cells (Figure 3.2). All subsequent immunohistochemistry experiments were 
performed using a sheep polyclonal antibody raised against human ERK5 provided by 
Professor Philip Cohen, University of Dundee (182).  Immunostaining with the 
commercial ERK5 and phospho ERK5 antibodies available was also assessed however 
poor results were observed. 
 
3.2.2  ERK5 expression in human prostate cancer and metastases 
To further define the patient cohorts, including those with metastatic lesions that 
may benefit from manipulation of ERK5 status, ERK5 immunoreactivity was studied in a 
prostate cancer TMA consisting of 48 primary prostate tumours. Consistent with data from 
previous TMA analysis, strong cytoplasmic ERK5 expression was found in prostate cancer 
with high levels of positive nuclear staining (moderate-strong cytoplasmic staining = 29%, 
positive nuclear staining = 62.5%).  Though not statistically significant, there was a trend 
between high levels of cytoplasmic ERK5 expression and high Gleason sum score (>7) and 
high serum PSA levels (>10) (data not shown).  Moderate-strong levels of cytoplasmic 
staining were observed in 63% cases of PIN/PIA.  Within the TMA, eleven cores of 
metastatic prostate tumour were examined, including liver (n=5), lung (n=2), lymph node 
(n=1) and soft tissue (n=3).  Among these metastatic lesions, ERK5 expression was 
consistently upregulated with both cytoplasm and nucleus immunoreactivity observed at 
high levels (73%, 8 out 11, Figure 3.3).  Two liver metastases and 1 soft tissue metastases 
showed no nuclear ERK5 immunoreactivity.  Hence, our expression analysis supports 
ERK5 as a potential target for therapy in prostate cancer sufferers particularly in those with 
castrate resistant and/or metastatic disease. 
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FIGURE 3.2  Optimisation of ERK5 antibody for immunohistochemistry 
 
 
 
 
Immunohistochemical analysis of cell pellets (x40 magnification) showing upregulated 
ERK5 expression in PC3-ERK5 cells under optimal growth condition compared to PC3 
cells transfected with empty vector control.  Insets represent control staining omitting 
primary antibody. 
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FIGURE 3.3  Immunohistochemistry of ERK5 expression in human prostate cancer 
and metastases  
 
A  BPH (1+ immunoreactivity) 
B  PIN (1+ immunoreactivity) 
C  Gleason 3+4 prostate cancer (3+ immunoreactivity with positive nuclear staining) 
D  Gleason 5+4 prostate cancer (3+ immunoreactivity with positive nuclear staining) 
E   Liver metastasis (3+ immunoreactivity with positive nuclear staining) 
F  Soft tissue metastasis (2+ immunoreactivity with positive nuclear staining) 
G  Lung metastasis (1+ immunoreactivity with positive nuclear staining) 
H  Lymph node metastasis (2+ immunoreactivity with positive nuclear staining)   73
 
 
3.2.3  ERK5 in prostate cancer cell lines 
ERK5 expression was examined in a panel of human prostate cancer cell lines 
maintained in full culture medium (Figure 3.4).  DU145 demonstrated the strongest level 
of ERK5 expression.  As shown previously ERK5 is present in both androgen sensitive and 
androgen insensitive LNCaP cells however there is marginal stronger expression in the 
androgen insensitive cell line (184).  Exogenous ERK5 expression in the PC3 ERK5 cell 
line is shown at a higher molecular weight than the endogenous ERK5 due to the presence 
of a GFP tag in the fusion protein, increasing its size by approximately 27kDa. 
High levels of both endogenous and exogenous ERK5 are demonstrated in PC3 
ERK5 cells.  However, with increased passage, I observed that the level of exogenous 
expression decreases (Figure 3.5).  All experiments with this cell line therefore were 
performed with low passage number to ensure optimal levels of ERK5 overexpression.  
There was no GFP expression evident on western blotting in the PC3 ERK5 cell line even 
at low passage.  Low expression levels of GFP were observed using the confocal 
microscope.  The reason for the discrepancy in levels of GFP: ERK5 is unclear. PC3 EV 
cells showed a decrease in GFP expression with increased passage. 
 
3.2.4  ERK5 siRNA - Transfection test 
Using the confocal microscope green fluorescent siRNA (Alexa Fluor 488) 
transfection was observed.  Optimal conditions were regarded as those in which the highest 
rate of transfection was achieved with the lowest rate of cell death, assessed by cell 
adherence.  Various conditions were tested, altering the concentrations of siRNA and the 
transfection reagent (HiPerfect) in each.  Using a 10nM siRNA concentration with the 
lowest volume of transfection reagent appeared to have the highest rate of transfection with 
no significant loss of cells.  Figure 3.6 shows the images taken from this optimal 
transfection well. 
Successful knockdown of exogenous and endogenous ERK5 was achieved from 48 
hours onwards in PC3 ERK5 cells with no associated change in ERK1/2 levels (Figure 
3.7).  Knockdown of endogenous ERK5 was also observed in the parental PC3 cells when 
transfected with ERK5 siRNA.  ERK5 phosphorylation status was examined in PC3 cells 
72 hours post siRNA transfection.  Phosphorylation levels were suppressed in the ERK5 
siRNA cells compared with the controls (Figure 3.8). 
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FIGURE 3.4  ERK5 expression in prostate cancer cell lines 
 
 
FIGURE 3.5  Exogenous ERK5 expression in PC3 ERK5 cells 
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FIGURE 3.6  Optimal transfection with green fluorescent siRNA (Alexa Fluor 488) 
 
 
FIGURE 3.7  ERK5 knockdown in PC3 and PC3 ERK5 cells 
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FIGURE 3.8  ERK5 siRNA inhibits ERK5 phosphorylation    
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3.2.5 Proliferation  assay 
As ERK5 overexpression has been shown to be associated with increased 
proliferation in vitro, I investigated the effects of siRNA mediated ERK5 knockdown in a 
proliferation assay.  Transfected PC3 ERK5 cells were counted at 24 hour intervals post 
siRNA transfection and a significant reduction in the rate of proliferation was observed 
upon ERK5 knockdown, when compared to the controls, p<0.005 (34.9% (non silencing 
siRNA) and 31.2% (no transfection) at 96 hours post transfection, Figure 3.9). 
 
3.2.6 Migration  assay 
We next tested the effects of ERK5 knockdown on cell motility.  Untransfected and 
control transfected PC3-ERK5 cells display high levels of random motility with a 
combination of amoeboid and mesenchymal movement.  Amoeboid movement is a 
crawling-like type of cell movement accomplished by protrusion of the cytoplasm of the 
cell involving the formation of pseudopodia.  Mesenchymal cells on the other hand are 
characterized by a small cell body with a few cell processes that are long and thin.   
Reduction of ERK5 significantly decreased cell motility, when compared to the non-
silencing siRNA and untransfected cells (Figure 3.10A).  Both the accumulated and 
euclidean (directional) distances were significantly reduced when compared to the controls 
(p<0.005, Figures 3.10 B & C).  Hence, ERK5 function in PC3 appears to regulate cellular 
motility. 
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FIGURE 3.9  ERK5 knockdown results in reduced proliferation in PC3 ERK5 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5x10
5 PC3 cells were transfected with ERK5 siRNA and counted at 24 hour 
intervals up to 96 hours.  Non silencing siRNA (AS-ve) was used a control in 
addition to HiPerfect only.  A significant reduction in proliferation was 
observed in the ERK5 siRNA transfected cells compared to both controls.  
Each experiment was performed in triplicate and repeated 3 times. 
*p<0.005   79
 
FIGURE 3.10A  Migration plots for transfected cell lines 
 
FIGURE 3.10 B & C 
ERK5 knockdown reduces accumulated and euclidean distance in PC3 ERK5 cells 
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3.2.7 Invasion  assay 
Data from our laboratory have recently revealed that ERK5 over-expression is 
closely associated with the presence of metastatic prostate cancer and unfavourable patient 
survival outcome (184).  I therefore wanted to test if ERK5 drives cellular invasion in a 
dose dependent manner and performed in vitro invasion assays using both parental PC3 
and PC3-ERK5 cells.  In keeping with our previous observation, PC3-ERK5 cells have an 
enhanced invasive phenotype when compared to parental PC3 cells, with around 25 (27+/- 
15/9) and 10 (10+/-4) cells per field respectively (Figure 3.11A and B).  Upon transfection 
with ERK5 targeted siRNA, the invasive capability of PC3 was significantly inhibited: 2.1 
and 1.97 fold reduction when compared with control siRNA transfected and untransfected 
PC3 cells (p<0.005) (Figure 3.11 A).  It was interesting to note that PC3-ERK5 cells are 
proportionally more sensitive to ERK5 manipulation in the invasion assay, with a 3.5 and 
3.4 fold reduction when ERK5 expression was knockdown, when compared with control 
siRNA and untransfected PC3-ERK5 cells (p<0.005)(Figure 3.11 B). 
 
FIGURE 3.11 ERK5 inhibition reduces invasion in PC3 and PC3 ERK5 cells 
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3.2.8  ERK5 over- or under-expression does not alter NFκB signalling 
Using PC3 cells as a model system, we tested if siRNA meditated knockdown of 
ERK5 expression may result in reduced NFκB activities, as assessed by the level of 
phospho-p65.  The phospho-p65 antibody (Cell Signalling #3031) used detects p65 only 
when phosphorylated at serine 536 and does not cross-react with the p50 subunit or other 
related proteins.  While ERK5 targeted siRNA drastically suppressed ERK5 expression, 
the level of total and phospho-p65 remained unchanged when compared to negative control 
siRNA and untransfected PC3 cells (Figure 3.12A).  In addition, in PC3-ERK5 cells, the 
level of total and phospho-p65 did not appear to be affected by the presence of increased 
ERK5 expression (Figure 3.12B). 
 
 
FIGURE 3.12   ERK5 expression does not change p65 levels 
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3.2.9  ERK5 overexpression and p65 levels - Xenograft studies 
In order to examine if there was nuclear co-localisation of ERK5 and NFκB we 
used PC3-ERK5 generated subcutaneous xenograft tissue for immunostaining.  This tissue 
was selected as our group have previously demonstrated that ERK5 promotes both in vitro 
and in vivo growth of these cells (184).  Overall, 8 xenografts were studied, at both high 
(x20) and low magnification (x5) and serial sections were stained for ERK5 and total p65 
expression.  p65 immunoreactivity in the PC3-ERK5 xenografts was noted to vary widely 
with different staining intensities within individual tumours and also among different 
tumours.  In addition, there did not appear to be any correlation between p65 and ERK5 
staining patterns.  In Figure 3.13, there was strong and fairly homogeneous nuclear ERK5 
immunoreactivity in the PC3-ERK5 cells, which contrast to the infrequent expression of 
nuclear (activated) p65 with the majority of ERK5 positive expressing detectable p65.   
Xenografts derived from PC3 EV cells were also stained for p65 and did not reveal any 
trend for association between nuclear ERK5 and p65 expression (data not shown).  These 
results suggest that there is no significant relationship between ERK5 and NFκB p65 
protein expression in these prostate cancer xenografts and corroborates the results from 
Western blotting.  This work was carried out by a BSc student whom I supervised during 
her time in the laboratory. 
 
FIGURE 3.13   ERK5 and p65 immunostaining in PC3 ERK5 xenografts 
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3.2.10  Potential downstream markers of ERK5 activity 
In order to monitor ERK5 activity in future drug trials involving an ERK5 inhibitor 
it is necessary that a reliable downstream marker is identified.  Several downstream 
substrates for ERK5 have been described in the literature in addition to NFκB including 
p70S6 kinase, GSK-3, ribosomal-S6 and BAD(209;210). 
Therefore, in order to assess the potential role of these as a marker of activity in 
prostate cancer, their expression levels were examined in PC3 cells where ERK5 
expression was inhibited using siRNA transfection.  Surprisingly none the known ERK5 
targets were altered when ERK5 levels were suppressed. (Figure 3.14)  It may be that these 
targets previously described are not downstream of ERK5 in prostate cancer cells or that 
other upstream pathways which would not be affected by ERK5 knockdown continue to 
have contributory effects.  Complete knockdown of ERK5 was not achieved with ERK5 
siRNA and this may also lead to lack of effect noted on the downstream markers. 
Due to time constraints this was not explored further.  Given more time it would of been 
interesting to reassess the effect of ERK5 knockdown on these known targets by using 
serum starved cells and by performing a timecourse experiment with EGF stimulation. 
 
FIGURE 3.14   Potential downstream markers of ERK5 signalling 
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3.3 Discussion 
Consistent with previous data, ERK5 nuclear expression is shown to be associated 
with aggressive prostate cancer in this study.  In addition strong levels of immunostaining 
have been shown in a range of metastatic tissue suggesting that ERK5 inhibition may be of 
therapeutic interest in both advanced prostate cancer and metastatic disease.  ERK5 
overexpression has previously been shown to enhance proliferation, migration and 
invasion in PC3 cells (184).  By using siRNA as a method of suppressing ERK5, we have 
shown that ERK5 inhibition results in a significant reduction in proliferation, migration 
and invasion in vitro.  This data confirms that targeting ERK5 in prostate cancer is an 
attractive therapeutic candidate.  A Cancer Research Technology Drug Development 
programme is currently focusing on ERK5 as an anti-cancer target.  Of particular interest, 
two MEK5 inhibitors (BIX02188 and BIX02189) have recently been identified.   
Successful inhibition of ERK5 phosphorylation was achieved using these novel 
compounds in HeLa cells (211).  There is currently no data of either of these MEK5 
inhibitors  in vivo.  Future work will therefore focus on the biological effect of these 
MEK5/ERK5 inhibitors on prostate cancer both in vitro and in murine models to assess if 
suitable for a future clinical trial.    
NFκB has been shown to be constitutively active in prostate cancer and recent 
evidence suggests that ERK5 and NFκB may interact in tumourigenesis.  The ERK5 
pathway has been shown to mainly target the localisation and activation of the p65 
component of NFκB (208).  
This study is the first to examine the relationship of ERK5 and NFκB in prostate 
cancer cells.  Immunohistochemistry and Western blotting were used to assess the effect on 
NFκB by altering ERK5 expression in PC3 cells.  Expression levels of p65 protein were 
measured because the p65/p50 heterodimer is the most abundant and transcriptionally 
active form of NFκB (196) . Contrary to previous studies, there was no evidence of 
changes in the total NFκB p65 expression caused by over- or under-expression of ERK5. 
In addition, phospho-p65 level was also unchanged by ERK5 siRNA.  Consistent with this 
in vitro data, NFκB p65 and ERK5 staining did not correlate in human prostate cancer 
xenografts.  
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4  The relationship between ERK1/2 and ERK5 mediated signalling 
   in prostate cells   
 
4.1 Introduction   
The MAPK family consists of at least 4 members: ERK 1/2, JNK, p38 and ERK5.   
All are activated by extracellular stimuli such as growth factors and environmental stresses 
and are recognised to have important roles in cell proliferation, migration and 
differentiation.  It is now increasingly appreciated that complex cross talk further refine 
and control the activities of these and other signalling pathways. 
Similarities between the ERK 1/2 and ERK5 pathways are recognised both in their 
activation modes and functions.  It has recently been suggested that there may be cross-talk 
between these pathways as treatment with high dose (10µM) PD184352, a specific MEK1 
inhibitor prevents ERK5 activation (182). Treatment with low dose (1µM) PD184352 has 
also been shown to increase nuclear accumulation of ERK5 and MEF2 promotor driven 
luciferase activity (183) suggesting that when ERK1/2 activation is suppressed, ERK5 
activation is enhanced. 
The current considered model of ERK1/2 regards each isoform as interchangeable 
due to their similar regulation and downstream effects.  It has recently been proposed 
however that there may be significant functional differences between each isoform with 
ERK1 acting as a negative regulator and ERK2 as a positive regulator of cell proliferation 
(212;213).  It is thought that ERK1 may affect the overall signalling by antagonizing 
ERK2 activity. 
My aim in this chapter was to explore if individually ERK1 and ERK2 may ‘cross-
talk’ with ERK5 in prostate cancer cell signalling.   siRNA mediated knock down of each 
isoform was performed and their effects examined, including the effect on phosphorylation 
status as well as ERK5 activation by western blotting.  The functional effects of ERK1 and 
ERK2 knockdown on PC3 proliferation were also assessed. 
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4.2 Results 
4.2.1  ERK5 and PD184352 
PD184352 is a MEK1 inhibitor, which suppresses ERK1/2 activity at low doses (1-
3µM).  It has previously been reported that PD184352 also suppresses ERK5 activity at 
higher dosage (10µM)(182;184).   
ERK5 is activated 15 minutes post EGF stimulation with neglible levels observed 
in serum-starved cells (Figure 4.1).  Serum starved PC3 cells were therefore treated with 5-
50µM PD184352 prior to EGF stimulation in order to assess its role as an ERK5 inhibitor.  
ERK5 phosphorylation is maximal 15 minutes post EGF stimulation and therefore cells 
were harvested at this timepoint in order to highlight the effective reduction in 
phosphorylation when using PD184352.    Complete pERK1/2 inhibition was achieved 
with 5µM treatment with a significant reduction in ERK5 observed at 10µM (Figure 4.2).    
 
 
FIGURE 4.1  EGF activates ERK5 in serum starved PC3 cells 
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FIGURE 4.2  Inhibition of ERK1/2 and ERK5 in PC3 cells by PD184352 (0-50µM) at 
15 minutes post EGF stimulation 
 
 
 
 
 
 
4.2.2  ERK1 and ERK2 knockdown in prostate cancer cell lines 
Successful knockdown of ERK1, ERK2 and ERK1/2 was achieved in PC3 cells 
and using both the HiPerfect and Amaxa method of siRNA transfection (Figure 4.3).   
Analysis of ERK5 status showed that in full medium ERK5 activation was upregulated 
when ERK1 expression was suppressed by siRNA.  Initial results suggested that ERK5 
phosphorylation may be suppressed when ERK2 was knocked down however when 
repeated (2 further times), no change in ERK5 activation levels were observed.  As this 
result was not reproducible it is thought to not be real. 
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4.2.3  ERK1 and ERK5 phosphorylation 
To further examine the potential relationship between ERK1 and ERK5 signalling, 
a timecourse experiment with EGF stimulation was performed on the ERK1 and ERK2 
knockdown cells (Figure 4.4).  As reported previously (212), ERK1 knockdown resulted in 
enhanced ERK2 phosphorylation.  The duration of ERK5 activation also appeared 
prolonged in the ERK1 knockdown cells when compared to the non-silencing siRNA 
control.  In contrast when ERK2 was knocked down ERK1 activation was enhanced 
however no significant alteration in ERK5 activation status was observed.  ERK5 
phosphorylation status was also assessed in PC3 cells in which ERK1 and ERK2 were 
simultaneously knocked down.  Surprisingly, there was no alteration in ERK5 activation 
observed. 
In order to further investigate the association between ERK5 and ERK1/2, a 
timecourse experiment with ERK5 siRNA transfected PC3 cells was performed (Figure 
4.5). ERK1/2 phosphorylation appears to suppressed in the ERK5 knockdown cells.  Due 
to time constraints this experiment was only performed once and further work would need 
to be done in order to validate this preliminary finding.   
 
FIGURE 4.3  Effects of siRNA mediated ERK1 and/or ERK2 knockdown on ERK5 
status  
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FIGURE 4.4  ERK1 knockdown results in prolonged ERK5 phosphorylation  
 
 
FIGURE 4.5  ERK5 knockdown has no effect on ERK1 phosphorylation  
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4.2.4  ERK1 and ERK2 knockdown have separate effects on PC3 proliferation 
Recent published data suggests that ERK1 may be a negative regulator and ERK2 a 
positive regulator of proliferation.  In order to study the effects of each individual isoform 
on prostate cancer cell proliferation, serial cell counts were performed on transfected cells 
at 24-hour intervals.   An increase in proliferation was observed in ERK1 knockdown cells 
(p<0.005).  A decrease in proliferation was noted in ERK2 knockdown cells when 
compared to the negative control siRNA (p<0.005) however this was only observed at 96 
hours post transfection (Figure 4.6).   
 
 
FIGURE 4.6 ERK1 and ERK2 have individual effects on PC3 proliferation rates 
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4.3 Discussion   
Both the ERK1/2 and ERK5 MAPK pathways share a number of activators such as 
the EGF receptor (167), HER2 (215) and Src (169) as well as oncogene products such as 
Ras (167) and COT (170).  Studies using MEK inhibitors previously implied roles for 
ERK1/2 activation downstream of Ras and Raf in neoplastic transformation. Recent studies 
have shown however that these inhibitors block ERK5 activation as well at various 
concentrations making it difficult to conclude that only ERK1/2 activation is involved 
(182).   
To date little is known of the relationship between ERK1/2 and ERK5 signalling.  
Previous work suggests that inhibiting ERK1/2 enhanced MEK5 signalling through ERK5.  
Treatment with low dose PD184352 enhanced nuclear accumulation of ERK5 and led to a 
twofold increase in MEF2 promoter driven luciferase activity in Src transformed cells 
(183).  
The results of this study highlight a novel biochemical and functional relationship 
between ERK1 and ERK5.  Future experiments of this project would involve quantitation 
of downstream signalling e.g. by transfection of an ERK5 specific MEF2 luciferase 
construct in addition to ERK1 siRNA in PC3 cells.  In addition immunofluorescence of 
ERK5 in ERK1 knockdown cells may allow further understanding of the effect of ERK1 
on ERK5 phosphorylation and its nuclear trafficking. 
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5 ERK5  proteomics 
5.1 Introduction 
ERK5 has been shown to regulate the activity of several transcription factors 
including MEF2, c-Fos and Fra-1, Sap-1, c-Myc and NFκB (167;170;171;216;217).  In 
order to further investigate the ERK5 signalling network I attempted to immunoprecipate 
endogenous ERK5 in PC3 cells and use mass spectrometry analysis to characterise its 
interacting proteins. 
Exogenous ERK5 was also studied using FLAG tag ERK5 and stable isotope 
labelling with amino acids in cell culture (SILAC) which is a method used to study in vitro 
mass spectrometry (MS)-based quantitative proteomics.  SILAC involves incorporating a 
given ‘light’ or ‘heavy’ form of the amino acid into the proteins (218).  The method relies 
on the incorporation of amino acids with substituted stable isotopic nuclei (e.g. deuterium, 
13C, 15N) (See Figure 5.1).  In an experiment two cell populations are grown in culture 
media that is identical with the exception that one will contain a ‘light’ and the other a 
‘heavy’ form of a particular amino acid (e.g. 
12C and 
13C labelled L-lysine, respectively).  
The labelled form of the amino acid is then incorporated into all new synthesised proteins 
and after a number of cell divisions this amino acid will be replaced by its isotope labelled 
analogue.  The cells behave exactly like the control cells since there is negligible 
difference between the labelled and natural amino acid isotopes.   
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FIGURE 5.1  Overview of SILAC protocol 
 
The SILAC experiment consists of two distinct phases; an adaptation and an experimental 
phase.  During the adaptation phase, cells are grown in light and heavy SILAC media until 
the cells grown in the heavy media have fully incorporated the heavy amino acids 
(confirmed by MS).  Cell number can also be expanded during this phase to accomodate 
the required number for the desired experiment.  In the experimental phase, the two cell 
populations are treated differently in order to induce changes in the proteome.  The 
samples are then mixed equally and analysed by MS for protein identification and 
quantification. 
Modified from Ong et al 2007(219) 
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5.2 Results 
5.2.1 Titration  experiments 
Initial immunoprecipatation experiments involved optimising experimental 
technique and reagents.  Both total and phospho-specific ERK5 antibodies (Cell signalling 
and Upstate) were tested with protein A and G sepharose beads.  For each titration 
experiment a constant antibody:bead ratio was maintained while increasing volumes of 
bead:PC3 lysate were used.  Neither ERK5 antibody worked successfully with protein G 
beads as smearing was observed at higher bead volumes on western blot analysis (Figure 
5.2).  Protein A beads and the phospho ERK5 antibody also demonstrated smearing in the 
bead lane with no significant reduction in the supernatant (SN) lane as the bead 
concentration increased (Figure 5.3).  Successful pulldown of ERK5 was achieved when 
the Cell Signalling antibody and Protein A beads were cross linked resulting in significant 
reduction in total ERK5 levels in the supernatant lane being observed with increasing bead 
concentration (Figure 5.4).  Subsequent experiments were therefore performed using the 
antibody:bead ratio 5:1. 
 
FIGURE 5.2  ERK5 (Cell Signalling and Upstate) and Protein G beads 
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FIGURE 5.3  Phospho ERK5 and Protein A beads  
 
FIGURE 5.4  ERK5 (Cell Signalling) and Protein A beads 
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5.2.2 ERK5  identification 
In order to confirm adequate ERK5 pull down for mass spectrometry, an initial 
immunopreciptation experiment was performed using the results of the titration 
experiment.  PC3 cells maintained in full medium were lysed, incubated with the ERK5 or 
Rabbit IgG cross linked beads overnight and the eluated sample run on a gel.  Samples of 
the lysate post incubation and the eluate pre and post concentration were analysed by 
western blotting in parallel to confirm successful pulldown and optimal technique when 
concentrating the final sample (see section 2.10.2) (Figure 5.5).  Mass spectrometry 
analysis of the area of interest (approximately 95-130kda) confirmed identification of 
ERK5 (Mitogen-activated protein kinase 7 - Homo sapiens) (Figure 5.6).   ERK5 was not 
however the most abundant protein with only 8 peptide matches and 12% sequence 
coverage observed.    
 
FIGURE  5.5  Confirmation of successful ERK5 pulldown and satisfactory 
concentration step 
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FIGURE 5.6  Analysis of initial endogenous ERK5 pulldown 
 
Results
6.6 5 95678 155 Interleukin enhancer-binding factor 3 - Homo sapiens 15
4.8 4 96246 201 Elongation factor 2 - Homo sapiens  14
6.7 5 66149 259 Keratin, type II cytoskeletal 1 - Homo sapiens 13
8.9 7 89950 271 Transitional endoplasmic reticulum ATPase -Homo sapiens  12
12 8 89151 296 Mitogen-activated protein kinase 7 - Homo sapiens1 11
8.1 6 85006 316 Heat shock protein HSP 90-alpha - Homo sapiens 10
7.4 6 98420 373 Importin subunit beta-1 - Homo sapiens 9
10.5 8 92696 390 Endoplasmin precursor - Homo sapiens  8
15.8 12 76216 526 Splicing factor, proline- and glutamine-rich - Homo sapiens 7
14.6 11 76625 539 Nucleolin - Homo sapiens 6
13.4 10 105245 552 Alpha-actinin-4 - Homo sapiens 5
17.7 13 83554 601 Heat shock protein HSP 90-beta - Homo sapiens  4
14.9 16 105398 684 AP-2 complex subunit beta-1 - Homo sapiens 3
24.4 18 103563 928 Alpha-actinin-1 - Homo sapiens 2
21.8 22 108570 984 AP-2 complex subunit alpha-1 - Homo sapiens 1
Sequence
coverage %
Number of peptide
matches
Protein
Mass
Protein
Score Protein Description Hit
Band 1 (results from SwissProt Human search)
1. ERK-5 is equivalent to Mitogen-activated protein kinase 7
• BSA was also identified with a score of 636 and a 20% sequence coverage in an expanded search
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5.2.3 Pre  clearing 
A pre clearing step with rabbit serum was performed prior to immunoprecipatation 
in order to reduce contamination.  An initial experiment was performed using PC3 cell 
lysate incubated with rabbit serum however significant smearing was noted and analysis 
not feasible.  Therefore a second pre clearing experiment was performed with four samples 
of lysis buffer (1ml) instead of cell lysate.  Increasing volumes of rabbit serum were 
incubated with the buffer (5, 10, 25 and 50ul) prior to incubation with a constant volume of 
Protein A beads (100ul). These samples were then run on a gel and stained with coomassie 
blue (Figure 5.7).  All four lanes demonstrated significant levels of the heavy chain and 
therefore this optimisation step was abandoned. 
 
 
FIGURE 5.7  Pre clearing optimisation experiment 
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5.2.4 EGF  stimulation 
As shown previously ERK5 is activated 15 minutes post EGF stimulation with 
neglible levels observed in serum-starved cells (Figure 4.1).  Therefore I chose to perform 
immunoprecipatation with EGF treated PC3 cells at 2 time points (0 and 15 minutes) as a 
method of analysing potential ERK5 interacting proteins.  Western blotting was performed 
in parallel to confirm successful ERK5 pull down (Figure 5.8). Streaking and spreading of 
the samples was observed following coomassie staining, which meant that the sample was 
not suitable for analysis below 34kDa (Figure 5.9).  Our proteomics facility (supervised by 
Dr Willy Bienvenut) analysed the section of the gel above 34kDa and ERK5 was once 
again identified.  However, only 2 unique peptide matches were found for ERK5 in the 0 
minute sample with 6 being identified in the 15 minute sample (Figure 5.10) making it 
unclear if any pulled down proteins were authentic.   
 
 
FIGURE 5.8  Successful activation of ERK5 post EGF stimulation and corresponding 
ERK5 immunoprecipatation 
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FIGURE  5.9 EGF stimulation gel for mass spectrometry with marked area of 
analysis 
 
 
 
FIGURE 5.10   Results from exogenous EGF immunoprecipatation experiment 
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5.2.5 Exogenous  ERK5 
As endogenous ERK5 pulldown was suboptimal it was decided to try transient 
transfection using a FLAG tag ERK5 expression construct.  Transient transfection was 
assessed in both PC3 and HEK 293 cells.  Western blotting confirmed inefficient 
expression of ERK5 in PC3 cells transfected with the pCMV FLAG tag ERK5 plasmid; 
however high levels of transfected ERK5 expression were noted in the HEK 293 cells 
(Figure 5.11).  HEK293 cells are well recognised to transfect readily and their transfection 
efficacy was therefore evaluated alongside PC3 cells.  Due to time constraints the 
transfection efficacy of other prostate cancer cell lines were not assessed.  The drawback of 
using HEK293 for transfection is that it does not allow assessment of ERK5 in prostate 
cancer and only allows assessment of ERK5 overexpression.  SILAC can also be 
performed using other tagged proteins and therefore I initially considered using the PC3 
ERK5 cells discussed in Chapter 3.   These cells would have been preferable as the 
primary cells would have been a prostate cancer cell line.  GFP expression was not 
abundant in these cells however and pull down would not have been as efficient as the 
FLAG tag protein.  
In order to confirm adequate ERK5 pull down for mass spectrometry analysis an 
initial sample was run on a gel for analysis (Figure 5.12).  After elution with the FLAG 
peptide the beads were boiled in sample buffer in order to assess efficiency of the peptide 
elution step.  The corresponding western is shown in figure 5.13.   
Mass spectrometry analysis of band 1 confirmed identification of ERK5 (Mitogen-
activated protein kinase 7 - Homo sapiens) (Figure 5.12).   ERK5 was the most abundant 
protein in this band with 39 peptide matches and 37% sequence coverage observed.   Band 
2 identified heat shock protein (HSP) 90 α and β with 43 and 24 peptide matches 
respectively.   Keratin was also observed in this band, which is presumed to be a 
contaminant.  As a pilot experiment, no control was included in this initial experiment, and 
therefore it would not be appropriate to compare the relative association between different 
HSP90 subunits and ERK5.   
Following successful pull down of exogenous ERK5, HEK293 cells were grown in 
SILAC media.  After 7 days, cells in both the light and heavy medium were lysed and run 
on a gel (figure not shown).  Mass spectrometry analysis of the heavy labelled lysate 
showed no significant presence of unlabelled material, confirming successful incorporation 
for subsequent experiments. 
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FIGURE 5.11   Transient transfection of FLAG tag ERK5 in HEK293 and PC3 cells 
 
 
 
FIGURE 5.12   FLAGtag  ERK5  transfection in HEK293 cells allows successful 
pulldown of ERK5 for mass spectrometry 
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FIGURE 5.13   Transient transfection and pulldown of ERK5 in HEK293 cells 
 
 
 
5.2.6  ERK5 vs EV 
In order to identify ERK5 associating proteins an initial SILAC experiment was 
performed comparing 293 cells transfected with either the pCMV FLAG ERK5 
(Experiment 1 – heavy medium, Experiment 2 – light medium) or pCMV FLAG EV 
(Experiment 1 – light medium, Experiment 2 – heavy medium) plasmid).  Mass 
spectrometry identified unequal loading of samples in experiment 1 which then meant that 
only experiment 2 could be used for analysis and unfortunately due to time constraints I 
was unable to repeat this experiment.  This experiment identified a number of interesting 
proteins including Heat Shock Protein 90 (HSP 90), which has previously been identified 
as being associated with ERK5 activation (220).   
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5.2.7  Identification of ERK5 binding partners upon activation of the MEK5-ERK5 
Pathway 
Initial optimisation experiments using HEK293 cells for EGF stimulation revealed 
that when serum starved the 293 cells had problems with adherence.  Plates were therefore 
coated with poly-l lysine prior to adding the cells.  EGF stimulation of HEK293 transfected 
with pCMV ERK5 at 0 and 15 minutes (Figure 5.14) demonstrated a similar pattern of 
phospho ERK5 activation to that seen in prostate cancer cells (Figure 4.1). 
Cells were treated with 50ng/ml EGF and then lysed at 2 time points: 0 minutes 
(Experiment 1 – light medium, Experiment 2 – heavy medium) and 15 minutes 
(Experiment 1 – heavy medium, Experiment 2 – light medium).  Mass spectrometry 
identified unequal loading of samples in experiment 1 which then meant that only 
experiment 2 could be used for analysis and unfortunately due to time constraints I was 
unable to repeat this experiment. Once again the sample was analysed by our in house 
proteomic facility and a list of potential ERK5 binding partners generated for review 
(Figure 5.15 and 5.16).  Equal levels of ERK5 were noted in both timepoints (middle 
ratio=0.99, variation=0.01).  Interestingly HSP 90 was not significantly upregulated 
between the serum starved and EGF stimulated cells indicating that although HSP 90 does 
associate with ERK5 it is not involved in its activation.   
Overall, 302 proteins were positively identified, and among 125 of these were 
shown to be recruited by at least 2 fold.  Based on a combination of number of peptide 
matches and confidence of match a further (n=64) subgroup of proteins were thought to 
represent the interacting proteome of activated ERK5. Further bioinformatics and 
validation analysis will be required to formally characterise the individual interacting 
protein of ERK5 and their potential role in carcinogenesis.   
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FIGURE 5.14  
EGF stimulation of HEK293 pCMV ERK5 cells leads to ERK5 phosphorylation 
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FIGURE 5.15  Clear positive matches from EGF stimulation experiment 
 
Figure 5.15 and 5.16.  Summary of proteins identified from MS study on EGF stimulation 
experiment   Studied proteins were those with recruitment at 15 minutes following EGF 
stimulation (~2 fold or more) as indicated by signal (peak height) from individual peptide 
hits in MS analysis.  Data from experiments 1 and 2 are presented to show the respective 
fold of recruitment to ERK5.  Identified proteins with a large number of non-redundant 
peptides and a high recruitment ratio are considered to be ‘clear positive’ and are listed in 
figure 5.15.   Other identified proteins with only a medium number of non-redundant 
matches are considered as ‘potential hits’ and are listed in figure 5.16. 
 
    Experiment 1  Experiment 2 
Heterogeneous nuclear ribonucleoprotein D0  8.30  5.10 
Stress-induced-phosphoprotein 1  5.62  3.62 
Proliferation-associated protein 2G4  6.18  2.92 
Heterogeneous nuclear ribonucleoprotein K  4.81  4.08 
Caprin-1 4.42  3.42 
ATP-dependent DNA helicase 2 subunit 1  4.67  3.15 
Poly [ADP-ribose] polymerase 1  4.58  3.25 
Actin, cytoplasmic 1  3.58  4.12 
Heat shock 70 kDa protein 4  4.29  3.31 
Nucleolin 4.27  3.04 
Probable ATP-dependent RNA helicase DDX17  4.08  2.70 
ATP-dependent RNA helicase DDX3X  3.54  3.14 
ATP-dependent DNA helicase 2 subunit 2  4.10  2.40 
Eukaryotic translation initiation factor 4B  2.97  3.42 
Putative elongation factor 1-alpha-like 3  3.44  2.94 
ATP-dependent RNA helicase A  3.37  2.88 
Elongation factor 1-gamma  3.41  2.39   107
FIGURE 5.16 Potential positive matches from EGF stimulation experiment 
 
 
 
 
  Experiment 1  Experiment 2 
RNA-binding protein EWS  7.19  2.83 
ELKS/RAB6-interacting/CAST family member 1  0  4.50 
Heterogeneous nuclear ribonucleoproteins A2/B1  1.99  6.13 
Nuclease-sensitive element-binding protein 1  3.76  0 
KH domain-containing, RNA-binding, signal   
transduction-associated protein 1 
0 3.57 
Structural maintenance of chromosomes protein 1A  3.57  0 
Spliceosome RNA helicase BAT1  3.42  0 
Golgi-specific brefeldin A-resistance guanine nucleotide 
exchange factor 1 
0 3.01 
Heterogeneous nuclear ribonucleoprotein M  2.80  3.12 
Eukaryotic translation initiation factor 2 subunit 1      0  2.83 
Stress-70 protein, mitochondrial  3.18  2.48 
Insulin-like growth factor 2 mRNA-binding protein 3  2.93  2.68 
Polypyrimidine tract-binding protein 1  2.32  3.15 
Insulin-like growth factor 2 mRNA-binding protein 1  3.10  2.34 
Probable ATP-dependent RNA helicase DDX5  3.12  2.31 
Eukaryotic translation initiation factor 3 subunit I      2.77  2.58 
Eukaryotic initiation factor 4A-I  2.67  0 
60S ribosomal protein L3  2.62  0 
Kappa-actin 2.62  0 
40S ribosomal protein S3  2.19  2.97 
Elongation factor 2  2.75  2.41 
Heterogeneous nuclear ribonucleoprotein R  2.74  2.36 
Heat shock protein 105 kDa  2.71  2.38 
60 kDa heat shock protein, mitochondrial  2.97  1.98 
Polyadenylate-binding protein 4  3.23  1.71 
Heterogeneous nuclear ribonucleoprotein U  2.65  2.16 
Eukaryotic translation initiation factor 3 subunit B  2.83  1.92 
78 kDa glucose-regulated protein  2.41  2.26 
Transitional endoplasmic reticulum ATPase  2.42  2.22 
Trifunctional enzyme subunit alpha, mitochondrial  2.30  0 
Nucleolar RNA helicase 2  2.67  1.81 
Heat shock 70 kDa protein 4L  1.82  2.66 
Interleukin enhancer-binding factor 3  2.21  2.23 
FACT complex subunit SSRP1  2.22  0 
Polyadenylate-binding protein 1  2.66  1.76 
Histone H1.4  1.95  2.46 
Eukaryotic translation initiation factor 3 subunit A     2.24  2.14 
Inosine-5'-monophosphate dehydrogenase 2  2.58  1.78 
26S proteasome non-ATPase regulatory subunit 11  2.23  1.99 
T-complex protein 1 subunit alpha  2.50  1.64 
Heterogeneous nuclear ribonucleoprotein H  2.06  2.06 
Clathrin heavy chain 1  2.26  1.75 
Glyceraldehyde-3-phosphate dehydrogenase  1.29  2.71 
26S proteasome non-ATPase regulatory subunit 2  2.24  1.74 
DNA replication licensing factor MCM3  2.01  1.95 
Eukaryotic translation initiation factor 3 subunit E       1.97  0 
T-complex protein 1 subunit theta  2.35  1.58   108
5.3 Discussion   
Endogenous protein immunoprecipatation is the method of choice when analysing 
protein interactions as it allows the most accurate analysis of events in the cell line chosen.  
Unfortunately in our experiments as is often the case inadequate amounts of endogenous 
protein were available despite numerous efforts to increase sample size. 
As an alternative to endogenous pulldown experiments, exogenous tagged cell lines 
can be used to facilitate a larger volume of protein complexes for analysis.  We used 
FLAG-tag epitope labelling, which is one of the most commonly used tags for 
immunoprecipation experiments.   
My experiments highlight some potential interacting proteins however these are 
very early results and future work is required to validate potential interacting proteins.  
Once these were confirmed their functional significance could be explored.  The main aim 
of this section of my work was to develop the methodology required for future ERK5 
proteomics work. 
HSP 90 is part of a chaperone complex for multiple proteins involved in cell 
signalling, proliferation and survival such as HER2, RAF and Src (221).  Previously it was 
thought that HSP90 was not involved in MAP kinase activities however recent evidence 
published suggests that ERK5 may be HSP90 dependent (220).  ERK5 kinase activity was 
abolished by HSP90 inhibition in vitro and ERK5 activity was lost when examined in a 
mutant HSP90 yeast strain.   
Inhibition of HSP90 is currently the focus of a number of phase I and II clinical 
trials.  As mentioned previously 17-AAG, a derivative of geldanamycin, is being 
investigated as an anti-cancer drug however initial results have shown no positive response 
following treatment (222).   
Our results support the theory that HSP90 does associate with ERK5 however 
contrary to Truman et al our results show that it is not involved in ERK5 activation.  The 
initial SILAC experiment performed with FLAG tag empty vector and ERK5 highlighted 
strong association between ERK5 and HSP90.  In the subsequent experiment with EGF 
stimulated FLAG tag ERK5 cells, HSP90 was confirmed to be present in both the 
unstimulated and stimulated cells in equal proportions.  This indicates that it is not 
involved in the activation of ERK5 in these cells.   
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6 Discussion 
6.1  Overview of project and summary of results 
Abnormal MEK5/ERK5 signalling has been shown to be important in prostate 
cancer and is thought to represent a potential target in for novel therapies in invasive 
disease (184).  The primary aim of this study was to validate previous expression data in 
human prostate cancer specimens and to investigate the effect of ERK5 inhibition both 
functionally and biochemically in prostate cancer cancer cell lines. 
As previous work has shown ERK5 to be overexpressed in CRPC (184) 
experiments in my project were performed using the PC3 cell line which is androgen 
independent aswell as the PC3-ERK5 overexpressing clone.  In order to validate these 
results repeat experiments using an androgen resistant cell line should have been 
performed.  
Cellular proliferation, motility and invasion was significantly reduced (p<0.005) 
when ERK5 was knocked down using siRNA.  Previous expression analysis performed by 
our group showed upregulated ERK5 expression in primary human prostate cancer 
specimens (184).  In this study, these results were validated and in addition high levels of 
cytoplasmic (55%) and nucleur (73%) immunoreactivity was also shown in a range of 
metastatic prostate tumours (n=11).   
Potential ‘cross-talk’ between ERK5 and ERK1/2 signalling was investigated in 
this study using siRNA for each individual isoform of ERK1/2.  My results showed that 
ERK1 knockdown resulted in increased ERK5 activation in addition to prolonged ERK2 
phosphorylation.  Proliferation studies were also performed in PC3 cells, the results of 
which support published data that ERK1 acts as a negative regulator and ERK2 as a 
positive regulator of cell proliferation. 
The final aim of my project was to develop a methodology to investigate the ERK5 
interacting proteome.  In order to do this a stepwise approach was adopted to first identify 
the correct antibody: bead ratio and optimal cell line to use.  As discussed in Chapter 5, I 
was unable to pulldown sufficient levels of endogenous ERK5 for immunoprecipation and 
therefore exogenous levels were examined.  A number of potential interacting proteins 
were identified however these preliminary results require validation by repeat experiments 
and further investigation. 
A more detailed discussion of results is included at the end of each of the results 
chapters (3-5).  The remainder of this chapter discusses ERK5 related biology and drug 
development as well as the potential role of an ERK5 inhibitor in clinical practice. 
   110
6.2  Drug development against implicated biological targets 
Previous clinical trials designed to evaluate novel agents (biological or small 
molecules) were frequently allocating patients to treatment regimes under investigation 
without prior analysis of gene expression and/or genotype.  High throughput gene 
expression profiling can be used to assess gene expression signatures from individual 
tumours.  Such methods of molecular profiling may offer an opportunity to link the 
oncogenic process with potential therapeutic strategies in the context of improved patient 
outcome (223).  Such a global approach will hopefully shed light on how individual 
biological cascades, including various signalling networks, interact to drive prostate 
carcinogenesis – this will have important implications in drug development. 
Another crucial aspect of drug development is the availability of biomarker(s) for a 
number of purposes, including their use in risk assessment, diagnosis - prognostic, 
stratification and therapy monitoring.  It is relevant to highlight the following requirements 
for drug development: (1) Robust method for in vivo assessment of quantifiable effects on 
the target of interest by the candidate agents is important, (2) Patient selection and 
stratification as guided by biologically relevant biomarker(s) will provide strong rationale 
for design of future clinical trials, (3) Clinical effects of the novel treatment on prostate 
cancer growth and progression will be assessed by the appropriate (surrogate) end points.  
Studies using many of the novel agents discussed in Chapter 1 (Sections 1.6 and 1.7) have 
attempted to identify markers as readouts for target inhibition or downstream signalling to 
guide patient selection and follow up e.g. pEGFR and pMAPK with EGFR inhibitors.  
Repeat tissue sampling however is not always feasible; more acceptable methods of 
sampling such as serum or urine would be preferable and may provide useful alternatives.      
Hence, there is an urgent need for validated urine or serum markers to evaluate the status 
of target of interest as well as the tumour as a whole.  Serum PSA is currently used as a 
biomarker in prostate cancer.  Its increasing use in recent years has facilitated early 
diagnosis of prostate cancer, reflected by a global rise in the incidence of prostate cancer 
since the 1990s.  PSA measurement has a number of drawbacks as it can also be elevated 
due to BPH or prostatitis leading to a significant number of false positive results.  There is 
a need for more specific biomarkers for prostate cancer, which can be used alone or in 
conjunction with PSA.  A number of biomarkers (serum and urine) are currently in trial. 
(224).   Prostate cancer antigen 3 (PCA3) is a gene which is overexpressed in prostate 
cancer and has been shown to have a higher specificity than PSA for malignancy (225).  It 
should be measured in the first-catch urine after prostatic massage and has been shown to 
be useful in patients to predict the presence of malignancy in men undergoing repeat   111
prostate biopsies (226).  Currently it is not funded for use in the National Health Service in 
the UK. 
Epigenetic changes have also been studied as both diagnostic and prognostic tools 
in prostate cancer.  It is apparent that genetically identical tumours have differing 
phenotypes due to altered epigenetic arrangements, which encompass a wide range of 
abnormalities at cell and molecular level, including post-translational modification (e.g. 
methylation, acetylation, ubiquitination, sumoylation), gene silencing (e.g. promoter hyper-
methylation) and growth arrest (e.g. senescence).  Hence, analysis of such assays for 
methylation changes or histone modifications in individual tumours has the potential to 
allow clinicians to predict patient prognosis and subsequent treatment stratification or 
direct targeted therapy can be considered.  
Targeted therapy in haematological cancers has proved more amenable than in 
solid tumours.  Haematological malignancies often arise from specific genetic mutations, 
e.g. Philadelphia chromosome with specific oncogenic translocation in bcl-abl, offering 
single molecular candidates for drug targeting.  In contrast solid tumours tend to be 
heterozygous and/or multi-focal involving multiple pathways.  Hence, the identification of 
the ‘single’ molecular target is much more difficult in solid tumours.  Indeed, for the vast 
majority of clinical solid tumour types, the knowledge of a single genetic or epigenetic 
lesion that critically drives carcinogenesis is missing.  In prostate cancer however recent 
studies have shown the majority of patients have a chromosomal rearrangement that fuses 
the gene for an androgen-regulated prostate-specific serine protease, TMPRSS2, with a 
member of the ETS family of transcription factors, most commonly ERG  (227).  The 
clinical implications of the fusion products remains unclear however it is anticipated that 
once this is understood TMPRSS2:ERG gene fusions may be used as a screening test or 
molecular target for novel therapies. 
Targeting a single molecule or pathway therefore may not be sufficient to 
significantly influence the malignant phenotype as signalling through other pathways may 
compensate for the effects of a single target affected by treatment.  Different 
pharmacological strategies have therefore been pursued to inhibit multiple pathways or 
multiple steps within the same pathway for use in advanced solid tumours.  Multi targeted 
agents or a combination of single targeted drugs may maximise effective target inhibition 
and have a complementary impact on downstream signalling.   
Sorafenib is a multi targeted TKI which is approved for clinical use in RCC (110).  
Sorafenib blocks receptor tyrosine kinase signalling (VEGFR, PDGFR, c-Kit and b-RAF)   112
and inhibits downstream signalling through the MAPK pathway preventing tumour growth 
by anti-angiogenic, anti-proliferative and /or pro-apoptotic effects.  Other novel muti-target 
inhibitors, which have been developed, include sunitinib, imatinib and lapatinib.  Multi 
targeted TKIs avoids drug-drug interactions and better compliance may be achieved with 
administration a single compound.  On the other hand, combining specific TKIs may 
increase treatment efficacy with exact titration for each agent allowing optimal target 
inhibition.  However, drug-drug interactions may potentially lead to altered responses. 
Another method, which may increase antitumour activity, is to combine different classes of 
inhibitors e.g. a monoclonal antibody and a TKI against the same single target.  In vitro 
and in vivo evidence has shown that combining monoclonal antibody therapy and TKI to 
target different molecular domains of the same receptor can potentiate cellular toxicity due 
to non-overlapping mechanisms of action and partially overcome acquired resistance to 
any single inhibitor.  A number of trials are currently studying the potential effects of 
combination regimes of targeted therapies with docetaxel.  Docetaxel improves survival in 
patients with hormone refractory disease by a mean of only 2.5 months (9;10).  Minimum 
survival improvements in this patient group would therefore convey significant results 
compared to docetaxel monotherapy, which is currently the only effective treatment option 
available. 
Understanding of the signalling pathways involved in prostate carcinogenesis has 
lead to the development of a number of potential new drugs with many reaching clinical 
trials. To date none of the targeted therapy have shown adequate efficacy for approval for 
routine usage. The discrepancy between preclinical and clinical findings may be a 
reflection of the fundamental differences between the currently available preclinical 
(usually murine) models and clinical cancer.  Current research on the development of a 
mouse model of prostate cancer focuses on using the Cre-loxP technology which would 
provide a conditional gene-knockout model.  This method is a more favourable model to 
study than traditional single or multi- gene knockout or knock-in models as it overcomes 
the problems of embryonic lethality, premature death or concerns that the cancer develops 
due to developmental defects (228).  Development of a relevant prostate cancer transgenic 
mouse model driven by validated molecular lesions may provide a meaningful model for 
clinical prostate cancer and may allow more clinically relevant assessment of novel anti-
cancer treatments prior to clinical trial. 
Several promising targets and agents are continuing to emerge and it is imperative 
that multi-disciplinary teams incorporating urological surgeons, oncologists and laboratory 
scientists are involved in bringing these novel treatments to clinical trial. 
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6.3  ERK5 as a drug target 
6.3.1  Which tumour types and which patient groups would be suitable for ERK5                             
             inhibition?                                                      
  Aberrant ERK5 expression has been demonstrated in a range of tumour tissue types, 
however the most significant data focuses on prostate and breast cancer.    
Based on data obtained by my study and previous data from our group, both metastatic and 
hormone (castrate) resistant prostate cancer have upregulated ERK5 expression.  These 
data would argue for benefit for ERK5 targeted therapy in prostate cancer.  When a clinical 
candidate for ERK5 inihibitor is made available, the patient cohort with either metastatic or 
castration resistant disease would be suitable for recruitment to a clinical trial.  The 
presence of ERK5 overexpression in tumour/metastatic tissue may indicate which patients 
should be targeted with an ERK5 inhibitor.  Patients would require repeat biopsies to 
assess ERK5 expression levels if therapy was to be commenced once castration resistant or 
metastatic disease developed. 
  MEK5/ERK5 signalling has been shown to also be important in breast carcinoma.  
High levels of ErbB2, a member of the ErbB family of tyrosine kinases, correlates with 
aggressive growth properties of breast cancer and is found in 20-30% of patients (29).  It 
has been shown that the MEK5/ERK5 pathway is constitutively activated in breast cancer 
cells overexpressing ErbB2 and that down regulation of this pathway significantly reduces 
the malignant growth of these cells (215).  ERK5 resides in the nucleus of cells that 
overexpress the ErbB2 receptor and recent work has shown that nuclear ERK5 favours 
MEF-2 dependant transcriptional activity and inhibits TRAIL  (tumour necrosis factor 
related apoptosis)-induced cell death (229). 
  Apoptosis is the primary route of cytotoxicity by many forms of anti-cancer therapy.  
Chemoresistance is a major therapeutic problem, allowing tumour cells the capability to 
progress and grow further resulting in a more aggressive metastatic phenotype.  Recent in 
vitro studies have highlighted the importance of the MEK5/ERK5 pathway in mediating 
breast cancer cells sensitivity to apoptotic inducing events (230).  Overexpression of 
MEK5 in APO- MCF7 cells suggests that this MAPK member may represent a significant 
potent survival molecule.  Further work will confirm if inhibition of this signalling 
pathway could promote for sensitising breast cancer cells to chemotherapeutic regimens 
and if successful this may be of significance in chemoresistant prostate cancer.  
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6.3.2  How would an ERK5 inhibitor be used: single agent or in combination? 
Many issues arise when developing targeted therapies for use in cancer.  A 
selective small molecule inhibitor of ERK5 would most likely be trialled initially in 
advanced prostate cancer patients in combination with docetaxel.  Docetaxel is currently 
the recommended treatment for men with metastatic CRPC.  Clinical trials for this patient 
group would therefore focus on comparing current recommended therapy against and in 
combination with the novel therapy under review.  As ERK5 has been shown to be 
overexpressed in castration resistant disease it would most likely also be used in clinical 
trials involving castration refractory cases either alone or in combination with other 
targeted therapies in order to tackle the heterogeneity of the disease. 
Crosstalk between ERK5 and ERK1/2 is a focus of current research and is 
discussed in Chapter 4.    Combining ERK5 inhibition with a MEK1/2 inhibitor may 
provide a more significant effect than single agent use.  By using combination therapy it 
may be that a lower dose of the MEK inhibitor could be used, increasing patient 
tolerability.  
 
6.3.3  Downstream biomarkers for ERK5 signalling 
A number of substrates of ERK5 are recognised however to date there is no specific 
and reliable downstream biomarker.  Further work is required to identify a downstream 
biomarker of which could be measured following treatment with an ERK5 inhibitor.   
Assessment of downstream targets of ERK5 was not studied in detail in this project 
however is recognised as an essential area which requires further work. 
 
6.3.4  Why would an ERK5 inhibitor work when MEK1/2 inhibitor in the past have        
not worked? 
The MEK/ERK signalling pathway plays a central role in the regulation of many of 
the cellular processes involved in carcinogenesis.  A number of MEK 1/2 inhibitors have 
entered phase I and II clinical trials.  However, these selective inhibitors have shown 
limited clinical effects in cancer patients with significant associated toxicities.  The first 
MEK 1/2 inhibitor to enter clinical trial was PD-184352 (also known as CI-1040).  One 
partial response in a pancreatic cancer patient was reported with 25% of patients achieving 
disease stabilization for 4 months or longer (231).  These results supported progression into 
a broad phase II study however no objective responses were documented.   
Pharmacokinetic studies showed up to 100-fold variation in drug exposure in different 
patients and the lack of efficacy in this phase II trial was therefore attributed to poor drug   115
bioavailability (214).  Second generation MEK inhibitors (PD0325901 and ARRY-
142886) were developed with reported superior potency and pharmacologic properties.   
Phase II trials of PD0325901 were abandoned due to severe toxicity.  This MEK inhibitor 
has very high potency and it is thought that these severe side effects suggested that 
complete inhibition of this pathway in normal tissues were not desirable.  ARRY-142886 
(AZD6244) however has shown more promising results with a lower incidence of reported 
toxicities and phase II trials are currently recruiting patients (232).   
The main issue, which raises concerns about the use of MEK1/2 inhibitors in 
cancer, is that MEK cannot be inhibited consistently in tumours at tolerable inhibitor 
doses.   It also remains unclear whether successful inhibition correlates with clinical 
outcome.  MEK inhibitors have been shown to have heightened sensitivity in tumours with 
B-Raf mutation and in vitro data shows that an activating RAS mutation showed much 
lower and more variable sensitivity.  Analysis of the tumour gene expression signature may 
therefore be useful to predict pathway activation and suitable patient selection.  
It may be that targeting the MEK/ERK5 pathway would not have the same toxicity 
profile due to their selective target inhibition.  Initial in vitro studies of the MEK5 inhibitor 
BIX02188 and BIX02189 showed inhibition of ERK5 phosphorylation in a dose dependant 
manner without affecting the phosphorylation of ERK1/2 (211). 
 
6.4  ERK5 related biology 
Details of ERK5 mediated carcinogenesis remains to be fully elucidated.  It is 
likely that it plays key roles in cellular migration/invasion, survival (including 
chemoresistance), and angiogensis (186;187;230).   My work on the ERK5 interacting 
proteome has provided a wealth of data on how ERK5 may function and the signalling 
partners involved.  Future validation will need to be performed and their functional 
significance in ERK5 driven phenotype tested.  It is particularly interesting to observe the 
binding of a number of RNA binding proteins to ERK5.  This raised the possibility that 
ERK5 complexed with RNA binding proteins may be important in the processing of RNA 
species.  Hence, future work in this topic and additional validation experiments of the 
ERK5 interacting proteome may yield key insight into the biology of ERK5 mediated 
signalling which may in turn provide hints for important downstream biomarkers that may 
be exploited as ‘read-outs’ for the functional state of ERK5 activities.  This will be very 
useful in the development and evaluation of novel ERK5 inhibitors. 
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6.5 ERK5  signalling  interactions 
Increased understanding of ERK5 signalling is required.  A number of activators of 
the ERK5 pathway have been identified including growth factors, tyrosine kinases and 
oncogene products such as Ras and COT (See section 1.8.1) however downstream targets 
of ERK5 are less well understood.   
ERK5 has been implicated in NFκB signalling which has itself been reported to 
play a role in prostate carcinogenesis.  To date there is no published data on their 
interaction in prostate carcinogenesis and therefore I investigated if ERK5 mediated 
signalling in prostate cancer cells involved the NFκB pathway.  Contrary to previous 
studies, NFκB levels in both in vitro and in vivo experiments did not show any correlation 
with ERK5 expression in this study. 
ERK5 and ERK 1/2 have recognised similarities in their activation modes and 
functions and crosstalk between these MAPK family members has been suggested 
(182;183).  This study is the first to demonstrate a novel relationship between ERK1 and 
ERK5 signalling in prostate cancer.  Such interaction may have clinical implications, and 
future trials of novel compounds will need to incorporate such cross talk into the design to 
ensure the in vitro and in vivo mode of action of any candidate compounds are adequately 
examined. 
 
6.6 Conclusion 
This study validates the importance of the ERK5 signalling pathway as a potential 
target for therapy and highlights a novel functional and biochemical relationship between 
ERK1 and ERK5 signalling.  A suitable, reliable downstream biomarker is essential for the 
development of an ERK5 inhibitor and although this study does not highlight such a 
specific target it does provide useful preliminary results for further work in this area.   
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